WO2008028168A2 - Serine-threonine protein kinase and parp modulators - Google Patents
Serine-threonine protein kinase and parp modulators Download PDFInfo
- Publication number
- WO2008028168A2 WO2008028168A2 PCT/US2007/077464 US2007077464W WO2008028168A2 WO 2008028168 A2 WO2008028168 A2 WO 2008028168A2 US 2007077464 W US2007077464 W US 2007077464W WO 2008028168 A2 WO2008028168 A2 WO 2008028168A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- optionally substituted
- ring
- alkyl
- heteroalkyl
- Prior art date
Links
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 title claims description 32
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 title claims description 32
- 238000000034 method Methods 0.000 claims abstract description 236
- 230000000694 effects Effects 0.000 claims abstract description 102
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 claims abstract description 56
- 230000004663 cell proliferation Effects 0.000 claims abstract description 21
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 18
- 102000001253 Protein Kinase Human genes 0.000 claims abstract description 13
- 108060006633 protein kinase Proteins 0.000 claims abstract description 13
- 150000001875 compounds Chemical class 0.000 claims description 472
- 125000001424 substituent group Chemical group 0.000 claims description 212
- -1 C2-C8 heteroalkenyl Chemical group 0.000 claims description 145
- 239000000203 mixture Substances 0.000 claims description 132
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 124
- 210000004027 cell Anatomy 0.000 claims description 113
- 239000003814 drug Substances 0.000 claims description 100
- 206010028980 Neoplasm Diseases 0.000 claims description 96
- 125000000623 heterocyclic group Chemical group 0.000 claims description 96
- 102000004169 proteins and genes Human genes 0.000 claims description 93
- 108090000623 proteins and genes Proteins 0.000 claims description 93
- 125000005843 halogen group Chemical group 0.000 claims description 89
- 229940124597 therapeutic agent Drugs 0.000 claims description 87
- 125000002837 carbocyclic group Chemical group 0.000 claims description 84
- 229910052760 oxygen Inorganic materials 0.000 claims description 81
- 125000003118 aryl group Chemical group 0.000 claims description 79
- 229910052717 sulfur Inorganic materials 0.000 claims description 78
- 150000003839 salts Chemical class 0.000 claims description 77
- 125000005842 heteroatom Chemical group 0.000 claims description 66
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 64
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 53
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 53
- 125000002252 acyl group Chemical group 0.000 claims description 50
- 125000000217 alkyl group Chemical group 0.000 claims description 49
- 125000001072 heteroaryl group Chemical group 0.000 claims description 46
- 125000006823 (C1-C6) acyl group Chemical group 0.000 claims description 44
- 201000011510 cancer Diseases 0.000 claims description 41
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims description 40
- 150000002148 esters Chemical class 0.000 claims description 40
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 39
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims description 37
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims description 37
- 229910052736 halogen Inorganic materials 0.000 claims description 37
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 36
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 36
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 35
- 125000004429 atom Chemical group 0.000 claims description 35
- 229910052757 nitrogen Inorganic materials 0.000 claims description 33
- 239000012661 PARP inhibitor Substances 0.000 claims description 32
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 claims description 32
- 230000033115 angiogenesis Effects 0.000 claims description 31
- 241000282414 Homo sapiens Species 0.000 claims description 29
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 27
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 26
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 26
- 208000002193 Pain Diseases 0.000 claims description 25
- 150000001732 carboxylic acid derivatives Chemical group 0.000 claims description 25
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims description 23
- 230000003993 interaction Effects 0.000 claims description 22
- 206010061218 Inflammation Diseases 0.000 claims description 21
- 150000002367 halogens Chemical class 0.000 claims description 21
- 230000004054 inflammatory process Effects 0.000 claims description 21
- 125000000520 N-substituted aminocarbonyl group Chemical group [*]NC(=O)* 0.000 claims description 20
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 20
- 230000002062 proliferating effect Effects 0.000 claims description 20
- 150000007942 carboxylates Chemical class 0.000 claims description 18
- 229910052739 hydrogen Inorganic materials 0.000 claims description 17
- 150000003536 tetrazoles Chemical class 0.000 claims description 17
- 238000011282 treatment Methods 0.000 claims description 17
- 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 claims description 16
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 16
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 claims description 14
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 14
- 150000001413 amino acids Chemical group 0.000 claims description 12
- 239000001257 hydrogen Substances 0.000 claims description 11
- 239000000758 substrate Substances 0.000 claims description 11
- 230000006907 apoptotic process Effects 0.000 claims description 10
- 125000004076 pyridyl group Chemical group 0.000 claims description 10
- 102100038606 Death-associated protein kinase 3 Human genes 0.000 claims description 9
- 101000956149 Homo sapiens Death-associated protein kinase 3 Proteins 0.000 claims description 9
- 101001001642 Xenopus laevis Serine/threonine-protein kinase pim-3 Proteins 0.000 claims description 9
- 210000004671 cell-free system Anatomy 0.000 claims description 9
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 8
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 8
- 208000002780 macular degeneration Diseases 0.000 claims description 8
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 claims description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- 239000007790 solid phase Substances 0.000 claims description 8
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 7
- 206010060862 Prostate cancer Diseases 0.000 claims description 7
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 7
- 150000003857 carboxamides Chemical class 0.000 claims description 7
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 7
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 102100032827 Homeodomain-interacting protein kinase 2 Human genes 0.000 claims description 6
- 102100032826 Homeodomain-interacting protein kinase 3 Human genes 0.000 claims description 6
- 101001066401 Homo sapiens Homeodomain-interacting protein kinase 2 Proteins 0.000 claims description 6
- 101001066389 Homo sapiens Homeodomain-interacting protein kinase 3 Proteins 0.000 claims description 6
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 claims description 6
- 229910019142 PO4 Inorganic materials 0.000 claims description 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 6
- 230000001594 aberrant effect Effects 0.000 claims description 6
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 6
- 201000002528 pancreatic cancer Diseases 0.000 claims description 6
- 230000035755 proliferation Effects 0.000 claims description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 5
- 210000000481 breast Anatomy 0.000 claims description 5
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
- 208000027866 inflammatory disease Diseases 0.000 claims description 5
- 210000004072 lung Anatomy 0.000 claims description 5
- 210000000496 pancreas Anatomy 0.000 claims description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 5
- 239000010452 phosphate Substances 0.000 claims description 5
- 210000002307 prostate Anatomy 0.000 claims description 5
- 238000012546 transfer Methods 0.000 claims description 5
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 4
- 229940024606 amino acid Drugs 0.000 claims description 4
- 125000001246 bromo group Chemical group Br* 0.000 claims description 4
- 230000002607 hemopoietic effect Effects 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 201000000849 skin cancer Diseases 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 229930192474 thiophene Natural products 0.000 claims description 4
- 102100032857 Cyclin-dependent kinase 1 Human genes 0.000 claims description 3
- 101710106279 Cyclin-dependent kinase 1 Proteins 0.000 claims description 3
- 102100023115 Dual specificity tyrosine-phosphorylation-regulated kinase 2 Human genes 0.000 claims description 3
- 101150009958 FLT4 gene Proteins 0.000 claims description 3
- 101001049990 Homo sapiens Dual specificity tyrosine-phosphorylation-regulated kinase 2 Proteins 0.000 claims description 3
- 101000648174 Homo sapiens Serine/threonine-protein kinase 10 Proteins 0.000 claims description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 3
- 102100024299 Maternal embryonic leucine zipper kinase Human genes 0.000 claims description 3
- 101710154611 Maternal embryonic leucine zipper kinase Proteins 0.000 claims description 3
- 102100028900 Serine/threonine-protein kinase 10 Human genes 0.000 claims description 3
- 102000016663 Vascular Endothelial Growth Factor Receptor-3 Human genes 0.000 claims description 3
- 125000000113 cyclohexyl group Chemical class [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 229960000310 isoleucine Drugs 0.000 claims description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 3
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 claims description 3
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- 229930182817 methionine Natural products 0.000 claims description 3
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims description 3
- 210000001672 ovary Anatomy 0.000 claims description 3
- 201000005787 hematologic cancer Diseases 0.000 claims description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 2
- 101710179684 Poly [ADP-ribose] polymerase Proteins 0.000 claims 12
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 claims 12
- 108091054872 CK2 family Proteins 0.000 claims 11
- 102000043139 CK2 family Human genes 0.000 claims 1
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 abstract description 68
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 abstract description 68
- 230000004071 biological effect Effects 0.000 abstract description 6
- 102000005403 Casein Kinases Human genes 0.000 abstract description 4
- 108010031425 Casein Kinases Proteins 0.000 abstract description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 73
- 239000007787 solid Substances 0.000 description 73
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 72
- 235000018102 proteins Nutrition 0.000 description 71
- 102000052052 Casein Kinase II Human genes 0.000 description 69
- 108010010919 Casein Kinase II Proteins 0.000 description 69
- 230000008569 process Effects 0.000 description 68
- 238000001990 intravenous administration Methods 0.000 description 60
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 57
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 55
- 239000000463 material Substances 0.000 description 45
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 42
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 39
- 241001465754 Metazoa Species 0.000 description 35
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 32
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 32
- 238000005160 1H NMR spectroscopy Methods 0.000 description 29
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 29
- 238000001704 evaporation Methods 0.000 description 29
- 230000008020 evaporation Effects 0.000 description 29
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 28
- 238000006243 chemical reaction Methods 0.000 description 28
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 26
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 24
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- 239000000243 solution Substances 0.000 description 24
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 23
- 238000002953 preparative HPLC Methods 0.000 description 22
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 21
- 125000003342 alkenyl group Chemical group 0.000 description 19
- 239000002904 solvent Substances 0.000 description 19
- 0 C*(NC(c1cccc(C(c2ccccc22)=NNC2=O)c1)=O)N1CCOCC1 Chemical compound C*(NC(c1cccc(C(c2ccccc22)=NNC2=O)c1)=O)N1CCOCC1 0.000 description 18
- 238000003556 assay Methods 0.000 description 18
- 229910052799 carbon Inorganic materials 0.000 description 18
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 17
- 125000000304 alkynyl group Chemical group 0.000 description 17
- 229910052938 sodium sulfate Inorganic materials 0.000 description 17
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 16
- 239000007832 Na2SO4 Substances 0.000 description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 15
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 14
- 229940002612 prodrug Drugs 0.000 description 14
- 239000000651 prodrug Substances 0.000 description 14
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 14
- 150000001412 amines Chemical class 0.000 description 13
- 238000001914 filtration Methods 0.000 description 13
- 125000002950 monocyclic group Chemical group 0.000 description 13
- SFHYNDMGZXWXBU-LIMNOBDPSA-N 6-amino-2-[[(e)-(3-formylphenyl)methylideneamino]carbamoylamino]-1,3-dioxobenzo[de]isoquinoline-5,8-disulfonic acid Chemical compound O=C1C(C2=3)=CC(S(O)(=O)=O)=CC=3C(N)=C(S(O)(=O)=O)C=C2C(=O)N1NC(=O)N\N=C\C1=CC=CC(C=O)=C1 SFHYNDMGZXWXBU-LIMNOBDPSA-N 0.000 description 12
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 12
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 12
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 12
- 229920006395 saturated elastomer Polymers 0.000 description 12
- 239000003039 volatile agent Substances 0.000 description 12
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 11
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 10
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 10
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 10
- 125000004122 cyclic group Chemical group 0.000 description 10
- 235000019439 ethyl acetate Nutrition 0.000 description 10
- 239000001632 sodium acetate Substances 0.000 description 10
- 235000017281 sodium acetate Nutrition 0.000 description 10
- 125000003107 substituted aryl group Chemical group 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 125000002947 alkylene group Chemical group 0.000 description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 239000000284 extract Substances 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 239000001301 oxygen Substances 0.000 description 9
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- 229940093499 ethyl acetate Drugs 0.000 description 8
- 125000005647 linker group Chemical group 0.000 description 8
- BEPHIMXUTWXXJJ-UHFFFAOYSA-N methyl 4-oxo-5h-thieno[3,2-c]quinoline-7-carboxylate Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2C2=C1C=CS2 BEPHIMXUTWXXJJ-UHFFFAOYSA-N 0.000 description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 8
- 239000007858 starting material Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 7
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 7
- 125000001153 fluoro group Chemical group F* 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- MXSXPCDVADEKHZ-UHFFFAOYSA-N 4-chlorothieno[3,2-c]quinoline-7-carbonitrile Chemical compound ClC1=NC2=CC(C#N)=CC=C2C2=C1C=CS2 MXSXPCDVADEKHZ-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical class C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 6
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
- 125000003545 alkoxy group Chemical group 0.000 description 6
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 6
- 125000003368 amide group Chemical group 0.000 description 6
- 125000002619 bicyclic group Chemical group 0.000 description 6
- 239000012267 brine Substances 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 125000001183 hydrocarbyl group Chemical group 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 6
- 210000002381 plasma Anatomy 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 6
- 150000003852 triazoles Chemical class 0.000 description 6
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 206010061309 Neoplasm progression Diseases 0.000 description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 150000001733 carboxylic acid esters Chemical class 0.000 description 5
- 125000000753 cycloalkyl group Chemical group 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 5
- 235000021317 phosphate Nutrition 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 239000011593 sulfur Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 230000005751 tumor progression Effects 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 4
- RAIPHJJURHTUIC-UHFFFAOYSA-N 1,3-thiazol-2-amine Chemical compound NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 description 4
- FUYOZIVWKHUWQX-UHFFFAOYSA-N 2-sulfamoylacetic acid Chemical compound NS(=O)(=O)CC(O)=O FUYOZIVWKHUWQX-UHFFFAOYSA-N 0.000 description 4
- CZWWCTHQXBMHDA-UHFFFAOYSA-N 3h-1,3-thiazol-2-one Chemical compound OC1=NC=CS1 CZWWCTHQXBMHDA-UHFFFAOYSA-N 0.000 description 4
- YAVSHDIJXOTQSY-UHFFFAOYSA-N 4-anilinothieno[3,2-c]quinoline-7-carbonitrile Chemical compound N=1C2=CC(C#N)=CC=C2C=2SC=CC=2C=1NC1=CC=CC=C1 YAVSHDIJXOTQSY-UHFFFAOYSA-N 0.000 description 4
- FFYFVQIUCOSRPH-UHFFFAOYSA-N 4-chlorothieno[3,2-c]quinoline Chemical compound ClC1=NC2=CC=CC=C2C2=C1C=CS2 FFYFVQIUCOSRPH-UHFFFAOYSA-N 0.000 description 4
- SIINIMHTUGVQHA-UHFFFAOYSA-N 4-oxo-5h-thieno[3,2-c]quinoline-7-carboxylic acid Chemical compound O=C1NC2=CC(C(=O)O)=CC=C2C2=C1C=CS2 SIINIMHTUGVQHA-UHFFFAOYSA-N 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 229910002666 PdCl2 Inorganic materials 0.000 description 4
- 108091000080 Phosphotransferase Proteins 0.000 description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
- 235000011054 acetic acid Nutrition 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 229950003476 aminothiazole Drugs 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 150000001450 anions Chemical class 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 125000004181 carboxyalkyl group Chemical group 0.000 description 4
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 4
- 238000003818 flash chromatography Methods 0.000 description 4
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 4
- 229940020967 gemzar Drugs 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- ADKGOXMEPLSPNN-UHFFFAOYSA-N methyl 2-bromothiophene-3-carboxylate Chemical compound COC(=O)C=1C=CSC=1Br ADKGOXMEPLSPNN-UHFFFAOYSA-N 0.000 description 4
- XSFXZXTUFUCVCQ-UHFFFAOYSA-N methyl 5-chloropyrimido[4,5-c]quinoline-8-carboxylate Chemical compound C1=NC=C2C3=CC=C(C(=O)OC)C=C3N=C(Cl)C2=N1 XSFXZXTUFUCVCQ-UHFFFAOYSA-N 0.000 description 4
- 150000002825 nitriles Chemical class 0.000 description 4
- 239000012299 nitrogen atmosphere Substances 0.000 description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 4
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 102000020233 phosphotransferase Human genes 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical class C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 4
- 150000003222 pyridines Chemical class 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- 229910052720 vanadium Inorganic materials 0.000 description 4
- IDUSDMZTKZZVAW-UHFFFAOYSA-N (2-amino-4-methoxycarbonylphenyl)boronic acid;hydron;chloride Chemical compound [Cl-].COC(=O)C1=CC=C(B(O)O)C([NH3+])=C1 IDUSDMZTKZZVAW-UHFFFAOYSA-N 0.000 description 3
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 3
- NIWIKUAWVYZYBD-UHFFFAOYSA-N 3h-dithiazol-4-amine Chemical class NC1=CSSN1 NIWIKUAWVYZYBD-UHFFFAOYSA-N 0.000 description 3
- FYSSSWKZHVZAFL-UHFFFAOYSA-N 4-oxo-5h-thieno[3,2-c]quinoline-7-carbonitrile Chemical compound O=C1NC2=CC(C#N)=CC=C2C2=C1C=CS2 FYSSSWKZHVZAFL-UHFFFAOYSA-N 0.000 description 3
- HJGFPNFAFSFDNN-UHFFFAOYSA-N 5-(3-ethynylanilino)pyrimido[4,5-c]quinoline-8-carboxylic acid Chemical compound C=1C(C(=O)O)=CC=C(C2=CN=CN=C22)C=1N=C2NC1=CC=CC(C#C)=C1 HJGFPNFAFSFDNN-UHFFFAOYSA-N 0.000 description 3
- KWIKUKWCLKBUMA-UHFFFAOYSA-N 5-anilino-3-(methylamino)pyrimido[4,5-c]quinoline-8-carboxylic acid Chemical compound N=1C(NC)=NC=C(C2=CC=C(C=C2N=2)C(O)=O)C=1C=2NC1=CC=CC=C1 KWIKUKWCLKBUMA-UHFFFAOYSA-N 0.000 description 3
- DSNJDLWXDIHPKN-UHFFFAOYSA-N 5h-thieno[3,2-c]quinolin-4-one Chemical compound O=C1NC2=CC=CC=C2C2=C1C=CS2 DSNJDLWXDIHPKN-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- 239000007993 MOPS buffer Substances 0.000 description 3
- 241000009328 Perro Species 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 3
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 238000001516 cell proliferation assay Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 3
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 3
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical group [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- SLPJGDQJLTYWCI-UHFFFAOYSA-N dimethyl-(4,5,6,7-tetrabromo-1h-benzoimidazol-2-yl)-amine Chemical compound BrC1=C(Br)C(Br)=C2NC(N(C)C)=NC2=C1Br SLPJGDQJLTYWCI-UHFFFAOYSA-N 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000003511 endothelial effect Effects 0.000 description 3
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 3
- 238000004020 luminiscence type Methods 0.000 description 3
- XNGYAJKIGFFHCA-UHFFFAOYSA-N methyl 2-acetamido-4-oxo-5h-[1,3]thiazolo[4,5-c]quinoline-7-carboxylate Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2C2=C1N=C(NC(C)=O)S2 XNGYAJKIGFFHCA-UHFFFAOYSA-N 0.000 description 3
- MSZVVEWLFFTCCE-UHFFFAOYSA-N methyl 2-bromo-4-oxo-5h-thieno[3,2-c]quinoline-7-carboxylate Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2C2=C1C=C(Br)S2 MSZVVEWLFFTCCE-UHFFFAOYSA-N 0.000 description 3
- AQMWJXTWTOCLPY-UHFFFAOYSA-N methyl 3-(methylamino)-5-oxo-6h-pyrimido[4,5-c]quinoline-8-carboxylate Chemical compound C1=C(C(=O)OC)C=C2NC(=O)C3=NC(NC)=NC=C3C2=C1 AQMWJXTWTOCLPY-UHFFFAOYSA-N 0.000 description 3
- XKYXAJCOMMLCII-UHFFFAOYSA-N methyl 4-chloro-[1,3]thiazolo[4,5-c]quinoline-7-carboxylate Chemical compound ClC1=NC2=CC(C(=O)OC)=CC=C2C2=C1N=CS2 XKYXAJCOMMLCII-UHFFFAOYSA-N 0.000 description 3
- GPCWPXAYQLXLBX-UHFFFAOYSA-N methyl 4-oxo-5h-[1,3]thiazolo[4,5-c]quinoline-7-carboxylate Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2C2=C1N=CS2 GPCWPXAYQLXLBX-UHFFFAOYSA-N 0.000 description 3
- MYZJIEWTRJTWCD-UHFFFAOYSA-N methyl 5-bromo-2-methylsulfanylpyrimidine-4-carboxylate Chemical compound COC(=O)C1=NC(SC)=NC=C1Br MYZJIEWTRJTWCD-UHFFFAOYSA-N 0.000 description 3
- XUPQZWPAEGFTMN-UHFFFAOYSA-N methyl 5-bromopyrimidine-4-carboxylate Chemical compound COC(=O)C1=NC=NC=C1Br XUPQZWPAEGFTMN-UHFFFAOYSA-N 0.000 description 3
- XCRKEOCRHSQXHV-UHFFFAOYSA-N methyl 5-chlorobenzo[c][2,6]naphthyridine-8-carboxylate Chemical compound C1=NC=C2C3=CC=C(C(=O)OC)C=C3N=C(Cl)C2=C1 XCRKEOCRHSQXHV-UHFFFAOYSA-N 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 229940080469 phosphocellulose Drugs 0.000 description 3
- 150000003053 piperidines Chemical class 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 2
- UOMIBBLLACIEDK-UHFFFAOYSA-N 2-[3-[(7-methoxycarbonylthieno[3,2-c]quinolin-4-yl)amino]phenyl]acetic acid Chemical compound N=1C2=CC(C(=O)OC)=CC=C2C=2SC=CC=2C=1NC1=CC=CC(CC(O)=O)=C1 UOMIBBLLACIEDK-UHFFFAOYSA-N 0.000 description 2
- YXKJATGNMRLGPL-UHFFFAOYSA-N 2-acetamido-4-oxo-5h-[1,3]thiazolo[4,5-c]quinoline-7-carboxylic acid Chemical compound C12=CC=C(C(O)=O)C=C2NC(=O)C2=C1SC(NC(=O)C)=N2 YXKJATGNMRLGPL-UHFFFAOYSA-N 0.000 description 2
- KDDBRDDBIVSCLX-UHFFFAOYSA-N 2-bromo-4-oxo-5h-thieno[3,2-c]quinoline-7-carboxylic acid Chemical compound O=C1NC2=CC(C(=O)O)=CC=C2C2=C1C=C(Br)S2 KDDBRDDBIVSCLX-UHFFFAOYSA-N 0.000 description 2
- UXZATHOFDZQOMY-UHFFFAOYSA-N 3-(cyclopropylamino)-5-[3-(trifluoromethyl)anilino]pyrimido[4,5-c]quinoline-8-carboxylic acid Chemical compound C=1C(C(=O)O)=CC=C(C2=CN=C(NC3CC3)N=C22)C=1N=C2NC1=CC=CC(C(F)(F)F)=C1 UXZATHOFDZQOMY-UHFFFAOYSA-N 0.000 description 2
- HVGTUNRGHOMOLH-UHFFFAOYSA-N 3-[[7-(2h-tetrazol-5-yl)thieno[3,2-c]quinolin-4-yl]amino]benzoic acid Chemical compound OC(=O)C1=CC=CC(NC=2C=3C=CSC=3C3=CC=C(C=C3N=2)C=2NN=NN=2)=C1 HVGTUNRGHOMOLH-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- OMZYUVOATZSGJY-UHFFFAOYSA-N 4,5,6,7-tetrabromo-2h-benzotriazole Chemical compound BrC1=C(Br)C(Br)=C(Br)C2=NNN=C21 OMZYUVOATZSGJY-UHFFFAOYSA-N 0.000 description 2
- QHXJAOLQHMYMJG-UHFFFAOYSA-N 4-(pyridin-3-ylmethylamino)thieno[3,2-c]quinoline-7-carboxylic acid Chemical compound N=1C2=CC(C(=O)O)=CC=C2C=2SC=CC=2C=1NCC1=CC=CN=C1 QHXJAOLQHMYMJG-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- DUPUQAYQFXVOCR-UHFFFAOYSA-N 4-anilinothieno[3,2-c]quinoline-7-carboxamide Chemical compound N=1C2=CC(C(=O)N)=CC=C2C=2SC=CC=2C=1NC1=CC=CC=C1 DUPUQAYQFXVOCR-UHFFFAOYSA-N 0.000 description 2
- BCFGGWKFYWJAOL-UHFFFAOYSA-N 4-chlorothieno[3,2-c]quinoline-7-carboxylic acid Chemical compound ClC1=NC2=CC(C(=O)O)=CC=C2C2=C1C=CS2 BCFGGWKFYWJAOL-UHFFFAOYSA-N 0.000 description 2
- ZDNMGTLLRXPHFB-UHFFFAOYSA-N 4-oxo-5h-thieno[3,2-c]quinoline-7-carboxamide Chemical compound O=C1NC2=CC(C(=O)N)=CC=C2C2=C1C=CS2 ZDNMGTLLRXPHFB-UHFFFAOYSA-N 0.000 description 2
- QYMARLQEROXMRP-UHFFFAOYSA-N 5-anilinobenzo[c][2,6]naphthyridine-8-carbonitrile Chemical compound C=1C(C#N)=CC=C(C2=CN=CC=C22)C=1N=C2NC1=CC=CC=C1 QYMARLQEROXMRP-UHFFFAOYSA-N 0.000 description 2
- QYMIPTWUHYWOFU-UHFFFAOYSA-N 5-chlorobenzo[c][2,6]naphthyridine-8-carbonitrile Chemical compound N1=CC=C2C(Cl)=NC3=CC(C#N)=CC=C3C2=C1 QYMIPTWUHYWOFU-UHFFFAOYSA-N 0.000 description 2
- RZJNYHIMNZGITB-UHFFFAOYSA-N 5-oxo-6h-benzo[c][2,6]naphthyridine-8-carbonitrile Chemical compound N1=CC=C2C(=O)NC3=CC(C#N)=CC=C3C2=C1 RZJNYHIMNZGITB-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 238000000040 CK2 assay Methods 0.000 description 2
- 229940122360 Casein kinase 2 inhibitor Drugs 0.000 description 2
- 102000003952 Caspase 3 Human genes 0.000 description 2
- 108090000397 Caspase 3 Proteins 0.000 description 2
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 2
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 2
- DHCLVCXQIBBOPH-UHFFFAOYSA-N beta-glycerol phosphate Natural products OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 2
- GHRQXJHBXKYCLZ-UHFFFAOYSA-L beta-glycerolphosphate Chemical compound [Na+].[Na+].CC(CO)OOP([O-])([O-])=O GHRQXJHBXKYCLZ-UHFFFAOYSA-L 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 238000000114 cell free in vitro assay Methods 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000013058 crude material Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 150000001923 cyclic compounds Chemical class 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- TXCDCPKCNAJMEE-UHFFFAOYSA-N dibenzofuran Chemical compound C1=CC=C2C3=CC=CC=C3OC2=C1 TXCDCPKCNAJMEE-UHFFFAOYSA-N 0.000 description 2
- 239000013024 dilution buffer Substances 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- KAJIRIIDTCRPKH-UHFFFAOYSA-N ethyl 3-bromopyridine-4-carboxylate Chemical compound CCOC(=O)C1=CC=NC=C1Br KAJIRIIDTCRPKH-UHFFFAOYSA-N 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 2
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000000021 kinase assay Methods 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 2
- NFFLDRRUYJLBRB-UHFFFAOYSA-N methyl 2-acetamido-5-bromo-1,3-thiazole-4-carboxylate Chemical compound COC(=O)C=1N=C(NC(C)=O)SC=1Br NFFLDRRUYJLBRB-UHFFFAOYSA-N 0.000 description 2
- PGQTUEVFEGMRNL-UHFFFAOYSA-N methyl 2-amino-4-bromo-5h-1,3-thiazole-4-carboxylate Chemical compound COC(=O)C1(Br)CSC(N)=N1 PGQTUEVFEGMRNL-UHFFFAOYSA-N 0.000 description 2
- AOEXOMNOEZRIRY-UHFFFAOYSA-N methyl 3-methylsulfanyl-5-oxo-6h-pyrimido[4,5-c]quinoline-8-carboxylate Chemical compound CSC1=NC=C2C3=CC=C(C(=O)OC)C=C3NC(=O)C2=N1 AOEXOMNOEZRIRY-UHFFFAOYSA-N 0.000 description 2
- HYQFGTDKKXZBSZ-UHFFFAOYSA-N methyl 4-(3-hydroxypropoxy)thieno[3,2-c]quinoline-7-carboxylate Chemical compound OCCCOC1=NC2=CC(C(=O)OC)=CC=C2C2=C1C=CS2 HYQFGTDKKXZBSZ-UHFFFAOYSA-N 0.000 description 2
- KGHFBXGGLPKNHV-UHFFFAOYSA-N methyl 5-(3-hydroxypropyl)-4-oxothieno[3,2-c]quinoline-7-carboxylate Chemical compound O=C1N(CCCO)C2=CC(C(=O)OC)=CC=C2C2=C1C=CS2 KGHFBXGGLPKNHV-UHFFFAOYSA-N 0.000 description 2
- XVQZAZQCVIRLJV-UHFFFAOYSA-N methyl 5-anilino-3-methylsulfonylpyrimido[4,5-c]quinoline-8-carboxylate Chemical compound C=1C(C(=O)OC)=CC=C(C2=CN=C(N=C22)S(C)(=O)=O)C=1N=C2NC1=CC=CC=C1 XVQZAZQCVIRLJV-UHFFFAOYSA-N 0.000 description 2
- AUJMFWXVFMHABB-UHFFFAOYSA-N methyl 5-bromo-1,3-thiazole-4-carboxylate Chemical compound COC(=O)C=1N=CSC=1Br AUJMFWXVFMHABB-UHFFFAOYSA-N 0.000 description 2
- SPAHRPKPEPZZFG-UHFFFAOYSA-N methyl 5-bromo-2-(methylamino)pyrimidine-4-carboxylate Chemical compound CNC1=NC=C(Br)C(C(=O)OC)=N1 SPAHRPKPEPZZFG-UHFFFAOYSA-N 0.000 description 2
- KGPKLCIXRUGXLE-UHFFFAOYSA-N methyl 5-chloro-3-methylsulfanylpyrimido[4,5-c]quinoline-8-carboxylate Chemical compound CSC1=NC=C2C3=CC=C(C(=O)OC)C=C3N=C(Cl)C2=N1 KGPKLCIXRUGXLE-UHFFFAOYSA-N 0.000 description 2
- OKXJYDKHLBHDPH-UHFFFAOYSA-N methyl 5-oxo-6h-benzo[c][2,6]naphthyridine-8-carboxylate Chemical compound C1=NC=C2C3=CC=C(C(=O)OC)C=C3NC(=O)C2=C1 OKXJYDKHLBHDPH-UHFFFAOYSA-N 0.000 description 2
- WZCYVVYTURVKKJ-UHFFFAOYSA-N methyl 5-oxo-6h-pyrimido[4,5-c]quinoline-8-carboxylate Chemical compound C1=NC=C2C3=CC=C(C(=O)OC)C=C3NC(=O)C2=N1 WZCYVVYTURVKKJ-UHFFFAOYSA-N 0.000 description 2
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 230000000897 modulatory effect Effects 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- 150000002780 morpholines Chemical class 0.000 description 2
- 210000003739 neck Anatomy 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 125000004043 oxo group Chemical group O=* 0.000 description 2
- 230000020477 pH reduction Effects 0.000 description 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
- 150000003235 pyrrolidines Chemical class 0.000 description 2
- 150000007660 quinolones Chemical class 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229960004964 temozolomide Drugs 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 2
- 229960000303 topotecan Drugs 0.000 description 2
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 2
- 238000001665 trituration Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- JNELGWHKGNBSMD-UHFFFAOYSA-N xanthone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3OC2=C1 JNELGWHKGNBSMD-UHFFFAOYSA-N 0.000 description 2
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- HCBQCTAFMHAHIT-UHFFFAOYSA-N (2-amino-3-cyanophenyl)boronic acid Chemical compound NC1=C(C#N)C=CC=C1B(O)O HCBQCTAFMHAHIT-UHFFFAOYSA-N 0.000 description 1
- WXMONJRORKKLFA-UHFFFAOYSA-N (2-amino-3-methoxycarbonylphenyl)boronic acid Chemical compound COC(=O)C1=CC=CC(B(O)O)=C1N WXMONJRORKKLFA-UHFFFAOYSA-N 0.000 description 1
- XTCOKKVEUFHXBE-UHFFFAOYSA-N (2-amino-4-cyanophenyl)boronic acid;hydrochloride Chemical compound Cl.NC1=CC(C#N)=CC=C1B(O)O XTCOKKVEUFHXBE-UHFFFAOYSA-N 0.000 description 1
- OLHRJDVIFHDPLZ-UHFFFAOYSA-N (2-amino-4-methoxycarbonylphenyl)boronic acid Chemical compound COC(=O)C1=CC=C(B(O)O)C(N)=C1 OLHRJDVIFHDPLZ-UHFFFAOYSA-N 0.000 description 1
- DIRRKLFMHQUJCM-UHFFFAOYSA-N (2-aminophenyl)boronic acid Chemical compound NC1=CC=CC=C1B(O)O DIRRKLFMHQUJCM-UHFFFAOYSA-N 0.000 description 1
- ZDNOXKPUPYMWDD-UHFFFAOYSA-N (2-methoxycarbonylphenyl)boronic acid;hydrochloride Chemical compound Cl.COC(=O)C1=CC=CC=C1B(O)O ZDNOXKPUPYMWDD-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
- AVGHIQUXSVAJBC-UHFFFAOYSA-N 1,2-diazabicyclo[2.2.1]heptane Chemical compound C1C2CCN1NC2 AVGHIQUXSVAJBC-UHFFFAOYSA-N 0.000 description 1
- LRANPJDWHYRCER-UHFFFAOYSA-N 1,2-diazepine Chemical compound N1C=CC=CC=N1 LRANPJDWHYRCER-UHFFFAOYSA-N 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- SILNNFMWIMZVEQ-UHFFFAOYSA-N 1,3-dihydrobenzimidazol-2-one Chemical compound C1=CC=C2NC(O)=NC2=C1 SILNNFMWIMZVEQ-UHFFFAOYSA-N 0.000 description 1
- IDPURXSQCKYKIJ-UHFFFAOYSA-N 1-(4-methoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C=C1 IDPURXSQCKYKIJ-UHFFFAOYSA-N 0.000 description 1
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Substances C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- KSCPLKVBWDOSAI-UHFFFAOYSA-N 2,3,4,4a,5,6,7,7a-octahydro-1h-pyrrolo[3,4-b]pyridine Chemical compound N1CCCC2CNCC21 KSCPLKVBWDOSAI-UHFFFAOYSA-N 0.000 description 1
- DWPAWEOVWCYOAE-UHFFFAOYSA-N 2,3,4,4a,9,9a-hexahydro-1h-pyrido[3,4-b]indole Chemical compound C1=CC=C2C3CCNCC3NC2=C1 DWPAWEOVWCYOAE-UHFFFAOYSA-N 0.000 description 1
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 1
- UKHJNJFJCGBKSF-UHFFFAOYSA-N 2,5-diazabicyclo[2.2.1]heptane Chemical compound C1NC2CNC1C2 UKHJNJFJCGBKSF-UHFFFAOYSA-N 0.000 description 1
- JECYNCQXXKQDJN-UHFFFAOYSA-N 2-(2-methylhexan-2-yloxymethyl)oxirane Chemical compound CCCCC(C)(C)OCC1CO1 JECYNCQXXKQDJN-UHFFFAOYSA-N 0.000 description 1
- GYQBYVCBDHELEA-UHFFFAOYSA-N 2-amino-4-oxo-5h-[1,3]thiazolo[4,5-c]quinoline-7-carboxylic acid Chemical compound C12=CC=C(C(O)=O)C=C2NC(=O)C2=C1SC(N)=N2 GYQBYVCBDHELEA-UHFFFAOYSA-N 0.000 description 1
- UXGVMFHEKMGWMA-UHFFFAOYSA-N 2-benzofuran Chemical compound C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 description 1
- RVSXMPCELBYUSF-UHFFFAOYSA-N 2-bromothiophene-3-carboxylic acid Chemical compound OC(=O)C=1C=CSC=1Br RVSXMPCELBYUSF-UHFFFAOYSA-N 0.000 description 1
- WQMAANNAZKNUDL-UHFFFAOYSA-N 2-dimethylaminoethyl chloride Chemical compound CN(C)CCCl WQMAANNAZKNUDL-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- KQOIBXZRCYFZSO-UHFFFAOYSA-N 3,5-difluoroaniline Chemical compound NC1=CC(F)=CC(F)=C1 KQOIBXZRCYFZSO-UHFFFAOYSA-N 0.000 description 1
- RQFUZUMFPRMVDX-UHFFFAOYSA-N 3-Bromo-1-propanol Chemical compound OCCCBr RQFUZUMFPRMVDX-UHFFFAOYSA-N 0.000 description 1
- YWDVLONOSCLOSE-UHFFFAOYSA-N 3-[(7-methoxycarbonylthieno[3,2-c]quinolin-4-yl)amino]benzoic acid Chemical compound N=1C2=CC(C(=O)OC)=CC=C2C=2SC=CC=2C=1NC1=CC=CC(C(O)=O)=C1 YWDVLONOSCLOSE-UHFFFAOYSA-N 0.000 description 1
- AVXWWBFBRTXBRM-UHFFFAOYSA-N 3-bromopyridine-4-carboxylic acid Chemical compound OC(=O)C1=CC=NC=C1Br AVXWWBFBRTXBRM-UHFFFAOYSA-N 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- PNPCRKVUWYDDST-UHFFFAOYSA-N 3-chloroaniline Chemical compound NC1=CC=CC(Cl)=C1 PNPCRKVUWYDDST-UHFFFAOYSA-N 0.000 description 1
- NNKQLUVBPJEUOR-UHFFFAOYSA-N 3-ethynylaniline Chemical compound NC1=CC=CC(C#C)=C1 NNKQLUVBPJEUOR-UHFFFAOYSA-N 0.000 description 1
- WEQPBCSPRXFQQS-UHFFFAOYSA-N 4,5-dihydro-1,2-oxazole Chemical compound C1CC=NO1 WEQPBCSPRXFQQS-UHFFFAOYSA-N 0.000 description 1
- DSHCNJPTTSGRAX-UHFFFAOYSA-N 4-(3-hydroxypropoxy)thieno[3,2-c]quinoline-7-carboxylic acid Chemical compound OCCCOC1=NC2=CC(C(O)=O)=CC=C2C2=C1C=CS2 DSHCNJPTTSGRAX-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- LLOLWUBWVAYADM-UHFFFAOYSA-N 4-anilino-[1,3]thiazolo[4,5-c]quinoline-7-carboxylic acid Chemical compound N=1C2=CC(C(=O)O)=CC=C2C=2SC=NC=2C=1NC1=CC=CC=C1 LLOLWUBWVAYADM-UHFFFAOYSA-N 0.000 description 1
- MLZMWVQSLFCPIF-UHFFFAOYSA-N 4-anilino-n-methylsulfonylthieno[3,2-c]quinoline-7-carboxamide Chemical compound N=1C2=CC(C(=O)NS(=O)(=O)C)=CC=C2C=2SC=CC=2C=1NC1=CC=CC=C1 MLZMWVQSLFCPIF-UHFFFAOYSA-N 0.000 description 1
- ZJWIJPRRJBELMF-UHFFFAOYSA-N 4-anilinothieno[3,2-c]quinoline-7-carboxylic acid Chemical compound N=1C2=CC(C(=O)O)=CC=C2C=2SC=CC=2C=1NC1=CC=CC=C1 ZJWIJPRRJBELMF-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- IRCNDYNDHBXUMR-UHFFFAOYSA-N 4-oxo-5h-[1,3]thiazolo[4,5-c]quinoline-7-carboxylic acid Chemical compound O=C1NC2=CC(C(=O)O)=CC=C2C2=C1N=CS2 IRCNDYNDHBXUMR-UHFFFAOYSA-N 0.000 description 1
- QPYPBNRHDGXJMA-UHFFFAOYSA-N 4h-1,8-naphthyridin-3-one Chemical compound C1=CN=C2N=CC(=O)CC2=C1 QPYPBNRHDGXJMA-UHFFFAOYSA-N 0.000 description 1
- JPIYOGKAIULUIO-UHFFFAOYSA-N 5-(3,5-difluoroanilino)pyrimido[4,5-c]quinoline-8-carboxylic acid Chemical compound C=1C(C(=O)O)=CC=C(C2=CN=CN=C22)C=1N=C2NC1=CC(F)=CC(F)=C1 JPIYOGKAIULUIO-UHFFFAOYSA-N 0.000 description 1
- MUOKSQABCJCOPU-UHFFFAOYSA-N 5-(3-chloroanilino)benzo[c][2,6]naphthyridine-8-carboxylic acid Chemical compound C=1C(C(=O)O)=CC=C(C2=CN=CC=C22)C=1N=C2NC1=CC=CC(Cl)=C1 MUOKSQABCJCOPU-UHFFFAOYSA-N 0.000 description 1
- YITYPCHIVQKNBR-UHFFFAOYSA-N 5-(3-hydroxypropyl)-4-oxothieno[3,2-c]quinoline-7-carboxylic acid Chemical compound O=C1N(CCCO)C2=CC(C(O)=O)=CC=C2C2=C1C=CS2 YITYPCHIVQKNBR-UHFFFAOYSA-N 0.000 description 1
- MYUZKBJPMCQURR-UHFFFAOYSA-N 5-[2-(dimethylamino)ethyl]-4-oxothieno[3,2-c]quinoline-7-carboxylic acid Chemical compound O=C1N(CCN(C)C)C2=CC(C(O)=O)=CC=C2C2=C1C=CS2 MYUZKBJPMCQURR-UHFFFAOYSA-N 0.000 description 1
- HZZBITVSVYFOND-UHFFFAOYSA-N 5-bromopyrimidine-4-carboxylic acid Chemical compound OC(=O)C1=NC=NC=C1Br HZZBITVSVYFOND-UHFFFAOYSA-N 0.000 description 1
- RDMFHRSPDKWERA-UHFFFAOYSA-N 5H-Pyrido[4,3-b]indole Chemical compound C1=NC=C2C3=CC=CC=C3NC2=C1 RDMFHRSPDKWERA-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- YBFLHFDCBXZEEX-UHFFFAOYSA-N 7-(2h-tetrazol-5-yl)-5h-thieno[3,2-c]quinolin-4-one Chemical compound C=1C=C2C=3SC=CC=3C(=O)NC2=CC=1C1=NN=NN1 YBFLHFDCBXZEEX-UHFFFAOYSA-N 0.000 description 1
- PXPHNDRTHCIMIA-UHFFFAOYSA-N 7-(hydroxymethyl)-5h-thieno[3,2-c]quinolin-4-one Chemical compound O=C1NC2=CC(CO)=CC=C2C2=C1C=CS2 PXPHNDRTHCIMIA-UHFFFAOYSA-N 0.000 description 1
- BPMFPOGUJAAYHL-UHFFFAOYSA-N 9H-Pyrido[2,3-b]indole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=N1 BPMFPOGUJAAYHL-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- GDALETGZDYOOGB-UHFFFAOYSA-N Acridone Natural products C1=C(O)C=C2N(C)C3=CC=CC=C3C(=O)C2=C1O GDALETGZDYOOGB-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 101001027327 Bos taurus Growth-regulated protein homolog alpha Proteins 0.000 description 1
- OBBBUDXCMCHKDR-UHFFFAOYSA-N C(C1)C[I]2[I]1CCCC2 Chemical compound C(C1)C[I]2[I]1CCCC2 OBBBUDXCMCHKDR-UHFFFAOYSA-N 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 125000006725 C1-C10 alkenyl group Chemical group 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- MDMVNTIGIUOQAU-UHFFFAOYSA-O CC1(C=C2)c([s]cc3)c3C(Nc(cc3)ccc3Cl)=NC1C=C2C1=NN[NH2+]N1 Chemical compound CC1(C=C2)c([s]cc3)c3C(Nc(cc3)ccc3Cl)=NC1C=C2C1=NN[NH2+]N1 MDMVNTIGIUOQAU-UHFFFAOYSA-O 0.000 description 1
- LSSPHUZIFUQHNR-UHFFFAOYSA-N CC1(C=C2)c([s]cc3)c3C(Nc(cc3)ccc3F)=NC1C=C2c1nnn[nH]1 Chemical compound CC1(C=C2)c([s]cc3)c3C(Nc(cc3)ccc3F)=NC1C=C2c1nnn[nH]1 LSSPHUZIFUQHNR-UHFFFAOYSA-N 0.000 description 1
- SWCXAPOVHZLMII-UHFFFAOYSA-N CN(C)CC(Nc(cc1)nc(-c2c3cccc2)c1NC3=O)=O Chemical compound CN(C)CC(Nc(cc1)nc(-c2c3cccc2)c1NC3=O)=O SWCXAPOVHZLMII-UHFFFAOYSA-N 0.000 description 1
- YRVTWLAUEOBDFG-UHFFFAOYSA-N CN(CC1)CCN1c(cc1)nc(-c2ccccc22)c1NC2=O Chemical compound CN(CC1)CCN1c(cc1)nc(-c2ccccc22)c1NC2=O YRVTWLAUEOBDFG-UHFFFAOYSA-N 0.000 description 1
- GTJQPAGEYNLJJF-UHFFFAOYSA-N CN1CCN(CC(Nc(cc2)nc(-c3c4cccc3)c2NC4=O)=O)CC1 Chemical compound CN1CCN(CC(Nc(cc2)nc(-c3c4cccc3)c2NC4=O)=O)CC1 GTJQPAGEYNLJJF-UHFFFAOYSA-N 0.000 description 1
- JQUYQUASWUHALF-UHFFFAOYSA-N CNc(ncc1c(ccc(C(OC)=O)c2)c2n2)nc1c2Cl Chemical compound CNc(ncc1c(ccc(C(OC)=O)c2)c2n2)nc1c2Cl JQUYQUASWUHALF-UHFFFAOYSA-N 0.000 description 1
- KVUHCAXYWHQFLW-UHFFFAOYSA-N COC(c(nc(N)[s]1)c1Br)=O Chemical compound COC(c(nc(N)[s]1)c1Br)=O KVUHCAXYWHQFLW-UHFFFAOYSA-N 0.000 description 1
- PTODFGJIEFQQSX-UHFFFAOYSA-N COC(c(nc[s]1)c1[BrH]C)=O Chemical compound COC(c(nc[s]1)c1[BrH]C)=O PTODFGJIEFQQSX-UHFFFAOYSA-N 0.000 description 1
- IRLXQKPKNSFBOT-UHFFFAOYSA-N COc1cccc(Nc2nc3cc(C4NN=NN4)ccc3c3c2cc[s]3)c1 Chemical compound COc1cccc(Nc2nc3cc(C4NN=NN4)ccc3c3c2cc[s]3)c1 IRLXQKPKNSFBOT-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 206010062746 Carditis Diseases 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 102000016950 Chemokine CXCL1 Human genes 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- RZPKYVDAGPTICO-UHFFFAOYSA-O Fc(ccc(Nc1nc2cc(C3=NN[NH2+]N3)ccc2c2c1cc[s]2)c1)c1Cl Chemical compound Fc(ccc(Nc1nc2cc(C3=NN[NH2+]N3)ccc2c2c1cc[s]2)c1)c1Cl RZPKYVDAGPTICO-UHFFFAOYSA-O 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000005726 Inflammatory Breast Neoplasms Diseases 0.000 description 1
- 206010021980 Inflammatory carcinoma of the breast Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 208000005615 Interstitial Cystitis Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 229910010084 LiAlH4 Inorganic materials 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- DDFLFKTXUWPNMV-VZZOBAOTSA-N Nc1ncnc2c1nc[n]2C([C@@H]([C@@H]1O)O)OC1C(N1CCN(CC(Nc2cccc3c2CNC3=O)=O)CC1)=O Chemical compound Nc1ncnc2c1nc[n]2C([C@@H]([C@@H]1O)O)OC1C(N1CCN(CC(Nc2cccc3c2CNC3=O)=O)CC1)=O DDFLFKTXUWPNMV-VZZOBAOTSA-N 0.000 description 1
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010049088 Osteopenia Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 229910019213 POCl3 Inorganic materials 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010065159 Polychondritis Diseases 0.000 description 1
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010042938 Systemic candida Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- HXJUTPCZVOIRIF-UHFFFAOYSA-N Tetrahydrothiophene-1,1-dioxide, Natural products O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- FZEYVTFCMJSGMP-UHFFFAOYSA-N acridone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3NC2=C1 FZEYVTFCMJSGMP-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000012996 alamarblue reagent Substances 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- RJGDLRCDCYRQOQ-UHFFFAOYSA-N anthrone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 RJGDLRCDCYRQOQ-UHFFFAOYSA-N 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000011953 bioanalysis Methods 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 229910052681 coesite Inorganic materials 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 229910052906 cristobalite Inorganic materials 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- SJDXUKVTVORBEB-UHFFFAOYSA-N ethyl 3-[[7-(2h-tetrazol-5-yl)thieno[3,2-c]quinolin-4-yl]amino]benzoate Chemical compound CCOC(=O)C1=CC=CC(NC=2C=3C=CSC=3C3=CC=C(C=C3N=2)C=2NN=NN=2)=C1 SJDXUKVTVORBEB-UHFFFAOYSA-N 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- YLQWCDOCJODRMT-UHFFFAOYSA-N fluoren-9-one Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3C2=C1 YLQWCDOCJODRMT-UHFFFAOYSA-N 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 125000004474 heteroalkylene group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 208000021646 inflammation of heart layer Diseases 0.000 description 1
- 201000004653 inflammatory breast carcinoma Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 1
- BVIRSYKUGCSJIL-UHFFFAOYSA-N methyl 4-chlorothieno[3,2-c]quinoline-7-carboxylate Chemical compound ClC1=NC2=CC(C(=O)OC)=CC=C2C2=C1C=CS2 BVIRSYKUGCSJIL-UHFFFAOYSA-N 0.000 description 1
- LXDSAYLLXWOZPQ-UHFFFAOYSA-N methyl 5-(3,5-difluoroanilino)pyrimido[4,5-c]quinoline-8-carboxylate Chemical compound C=1C(C(=O)OC)=CC=C(C2=CN=CN=C22)C=1N=C2NC1=CC(F)=CC(F)=C1 LXDSAYLLXWOZPQ-UHFFFAOYSA-N 0.000 description 1
- MMNAVAKHOPKWOX-UHFFFAOYSA-N methyl 5-[2-(dimethylamino)ethyl]-4-oxothieno[3,2-c]quinoline-7-carboxylate Chemical compound O=C1N(CCN(C)C)C2=CC(C(=O)OC)=CC=C2C2=C1C=CS2 MMNAVAKHOPKWOX-UHFFFAOYSA-N 0.000 description 1
- PYQUQCIQQCVSOU-UHFFFAOYSA-N methyl 5-anilino-3-(methylamino)pyrimido[4,5-c]quinoline-8-carboxylate Chemical compound N=1C(NC)=NC=C(C2=CC=C(C=C2N=2)C(=O)OC)C=1C=2NC1=CC=CC=C1 PYQUQCIQQCVSOU-UHFFFAOYSA-N 0.000 description 1
- VVTBNGBSXDSXNC-UHFFFAOYSA-N methyl 5-anilino-3-methylsulfanylpyrimido[4,5-c]quinoline-8-carboxylate Chemical compound C=1C(C(=O)OC)=CC=C(C2=CN=C(SC)N=C22)C=1N=C2NC1=CC=CC=C1 VVTBNGBSXDSXNC-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- DILRJUIACXKSQE-UHFFFAOYSA-N n',n'-dimethylethane-1,2-diamine Chemical compound CN(C)CCN DILRJUIACXKSQE-UHFFFAOYSA-N 0.000 description 1
- MPTZTCJDULKFOI-UHFFFAOYSA-N n-phenyl-7-(2h-tetrazol-5-yl)thieno[3,2-c]quinolin-4-amine Chemical compound N=1C2=CC(C=3NN=NN=3)=CC=C2C=2SC=CC=2C=1NC1=CC=CC=C1 MPTZTCJDULKFOI-UHFFFAOYSA-N 0.000 description 1
- YOZNUAQXXJHWQZ-UHFFFAOYSA-N n-phenyl-8-(2h-tetrazol-5-yl)benzo[c][2,6]naphthyridin-5-amine Chemical compound N=1C2=CC(C=3NN=NN=3)=CC=C2C2=CN=CC=C2C=1NC1=CC=CC=C1 YOZNUAQXXJHWQZ-UHFFFAOYSA-N 0.000 description 1
- ZDPTWQAMIAECBP-UHFFFAOYSA-N n-phenylthieno[3,2-c]quinolin-4-amine Chemical compound N=1C2=CC=CC=C2C=2SC=CC=2C=1NC1=CC=CC=C1 ZDPTWQAMIAECBP-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- QNDVLZJODHBUFM-WFXQOWMNSA-N okadaic acid Chemical compound C([C@H](O1)[C@H](C)/C=C/[C@H]2CC[C@@]3(CC[C@H]4O[C@@H](C([C@@H](O)[C@@H]4O3)=C)[C@@H](O)C[C@H](C)[C@@H]3[C@@H](CC[C@@]4(OCCCC4)O3)C)O2)C(C)=C[C@]21O[C@H](C[C@@](C)(O)C(O)=O)CC[C@H]2O QNDVLZJODHBUFM-WFXQOWMNSA-N 0.000 description 1
- VEFJHAYOIAAXEU-UHFFFAOYSA-N okadaic acid Natural products CC(CC(O)C1OC2CCC3(CCC(O3)C=CC(C)C4CC(=CC5(OC(CC(C)(O)C(=O)O)CCC5O)O4)C)OC2C(O)C1C)C6OC7(CCCCO7)CCC6C VEFJHAYOIAAXEU-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- SFLGSKRGOWRGBR-UHFFFAOYSA-N phthalane Chemical compound C1=CC=C2COCC2=C1 SFLGSKRGOWRGBR-UHFFFAOYSA-N 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000009443 proangiogenesis Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- HFIMZLRNGHNVKX-UHFFFAOYSA-N propan-2-yl n-[3-(cyclopropylamino)-5-[3-(trifluoromethyl)anilino]pyrimido[4,5-c]quinolin-8-yl]carbamate Chemical compound C=1C(NC(=O)OC(C)C)=CC=C(C2=CN=C(NC3CC3)N=C22)C=1N=C2NC1=CC=CC(C(F)(F)F)=C1 HFIMZLRNGHNVKX-UHFFFAOYSA-N 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 229940043437 protein kinase A inhibitor Drugs 0.000 description 1
- 239000012656 protein kinase A inhibitor Substances 0.000 description 1
- 108010065251 protein kinase modulator Proteins 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- HDOUGSFASVGDCS-UHFFFAOYSA-N pyridin-3-ylmethanamine Chemical compound NCC1=CC=CN=C1 HDOUGSFASVGDCS-UHFFFAOYSA-N 0.000 description 1
- 150000005299 pyridinones Chemical class 0.000 description 1
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229910052682 stishovite Inorganic materials 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- IOGXOCVLYRDXLW-UHFFFAOYSA-N tert-butyl nitrite Chemical compound CC(C)(C)ON=O IOGXOCVLYRDXLW-UHFFFAOYSA-N 0.000 description 1
- 239000012414 tert-butyl nitrite Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- KRFNNUPEZDVMGG-UHFFFAOYSA-N thieno[3,2-c]quinolin-4-amine Chemical compound NC1=NC2=CC=CC=C2C2=C1C=CS2 KRFNNUPEZDVMGG-UHFFFAOYSA-N 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229910052905 tridymite Inorganic materials 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 208000027185 varicose disease Diseases 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/18—Ring systems of four or more rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/10—Aza-phenanthrenes
- C07D221/12—Phenanthridines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Definitions
- the invention relates in part to molecules having certain biological activities that include, but are not limited to, inhibiting cell proliferation, modulating serine-threonine protein kinase activity and modulating polymerase activity.
- Molecules of the invention can modulate casein kinase (CK) activity (e.g., CK2 activity) and/or poly(ADP-ribose)polymerase (PARP) activity.
- CK casein kinase
- PARP poly(ADP-ribose)polymerase
- the invention also relates in part to methods for using such molecules.
- the present invention in part provides chemical compounds having certain biological activities that include, but are not limited to, inhibiting cell proliferation, inhibiting angiogenesis, modulating protein kinase activity and modulating polymerase activity.
- Certain molecules can modulate casein kinase 2 (CK2) activity and/or a poly(ADP-ribose)polymerase (PARP) activity and can affect biological functions that include but are not limited to, inhibiting gamma phosphate transfer from ATP to a protein or peptide substrate, inhibiting angiogenesis, inhibiting cell proliferation and inducing cell apoptosis, for example.
- the present invention also in part provides methods for preparing novel chemical compounds, and analogs thereof, and methods of using the foregoing. Also provided are compositions comprising the above-described molecules in combination with other agents, and methods for using such molecules in combination with other agents.
- the compounds of the invention have the general formula (A) : wherein the group labeled ⁇ represents a 5-6 membered aromatic or heteroaromatic ring fused onto the ring containing Q 1 , wherein ⁇ is a 6-membered aryl ring optionally containing one or more nitrogen atoms as ring members, or a five membered aryl ring selected from thiophene and thiazole;
- the invention also includes the pharmaceutically acceptable salts of compounds of formula (A).
- Formula (A) represents a fused tricyclic ring system which is linked through either Q 1 or Q 2 to a group R , which is further described below.
- each Z 1 , Z 2 , Z 3 , and Z 4 is N or CR 3 ; each of Z 5 , Z 6 , Z 7 and Z 8 is CR 6 or N; each R 3 and each R 6 is independently H or an optionally substituted C1-C8 alkyl, C2-C8 heteroalkyl, C2-C8 alkenyl, C2-C8 heteroalkenyl, C2-C8 alkynyl, C2-C8 heteroalkynyl, C1-C8 acyl, C2-C8 heteroacyl, C6-C10 aryl, C5-C12 heteroaryl, C7-C12 arylalkyl, or C6-C12 heteroarylalkyl group, or each R 3 and each R 6 can be halo, OR, NR 2 , NROR, NRNR 2 , SR, SOR, SO 2 R, SO 2 NR 2 , NRSO
- R 4 is H or optionally substituted member selected from the group consisting of C 1 -C 6 alkyl, C2-C6 heteroalkyl, and C1-C6 acyl; each R is independently H or an optionally substituted member selected from the group consisting of C 1-10 alkyl, C 2-10 alkenyl, C 2-10 heteroalkyl, C 3-8 carbocyclic ring, and C 3-8 heterocyclic ring optionally fused to an additional optionally substituted carbocyclic or heterocyclic; or R 5 is a C 1-10 alkyl, C 2-10 alkenyl, or C 2-10 heteroalkyl substituted with an optionally substituted C 3-8 carbocyclic ring or C 3-8 heterocyclic ring; and in each -NR 4 R 5 , R 4 and R 5 together with N may form an optionally substituted 3-8 membered ring, which may optionally contain an additional heteroatom selected from N, O and S as a ring member; provided that when -NR 4 R 5 in Formula (I)
- each Z 1 , Z 2 , Z 3 , and Z 4 is N or CR 3 ; each of Z 5 , Z 6 , Z 7 and Z 8 is N or CR 6 ; none, one or two of Z 1 -Z 4 are N and none, one or two of Z 5 -Z 8 are N; each R 3 and each R 6 is independently H or an optionally substituted C1-C8 alkyl, C2-C8 heteroalkyl, C2-C8 alkenyl, C2-C8 heteroalkenyl, C2-C8 alkynyl, C2-C8 heteroalkynyl, C1-C8 acyl, C2-C8 heteroacyl, C6-C10 aryl, C5-C12 heteroaryl, C7-C12 arylalkyl, or C6-C12 heteroarylalkyl group,
- R 4 is H or an optionally substituted member selected from the group consisting of C1- C6 alkyl, C2-C6 heteroalkyl, and C1-C6 acyl; each R 5 is independently H or an optionally substituted member selected from the group consisting of C 1-10 alkyl, C 2-10 alkenyl, C 2-10 heteroalkyl, C 3-8 carbocyclic ring, and C 3-8 heterocyclic ring optionally fused to an additional optionally substituted carbocyclic or heterocyclic; or R 5 is a C 1-10 alkyl, C 2-10 alkenyl, or C 2-10 heteroalkyl substituted with an optionally substituted C 3-8 carbocyclic ring or C 3-8 heterocyclic ring; and in each -NR 4 R 5 , R 4 and R 5 together with N may form an optionally substituted 3-8 membered ring, which may optionally contain an additional heteroatom selected from N, O and S as a ring member; provided that when -NR 4 R 5 in Formula (I
- one, two, three or four of Z 5 , Z 6 , Z 7 and Z 8 are N.
- the ring nitrogen atoms may be adjacent (e.g., nitrogen atoms at Z 5 and Z 6 , Z 6 and Z 7 , or Z 7 and Z 8 ) or may be separated by one or two ring positions (e.g., nitrogen atoms at Z 5 and Z 7 , Z 6 and Z 8 or Z 5 and Z 8 ).
- at least one R substituent is a polar substituent, such as a carboxylic acid or a salt, an ester or a bioisostere thereof.
- At least one R 3 is a carboxylic acid-containing substituent or a carboxylate bioisostere, or a salt or ester thereof, for example. In some embodiments, at least one R 3 is a carboxylic acid-containing substituent or a salt thereof.
- polar substituent refers to any substituent having an electric dipole, and optionally a dipole moment (e.g., an asymmetrical polar substituent has a dipole moment and a symmetrical polar substituent does not have a dipole moment).
- Polar substituents include substituents that accept or donate a hydrogen bond, and groups that would carry at least a partial positive or negative charge in aqueous solution at physiological pH levels.
- a polar substituent is one that can accept or donate electrons in a non-covalent hydrogen bond with another chemical moiety.
- a polar substituent is selected from a carboxy, a carboxy bioisostere or other acid-derived moiety that exists predominately as an anion at a pH of about 7 to 8.
- Other polar substituents include, but are not limited to, groups containing an OH or NH, an ether oxygen, an amine nitrogen, an oxidized sulfur or nitrogen, a carbonyl, a nitrile, and a nitrogen- containing or oxygen-containing heterocyclic ring whether aromatic or non-aromatic.
- the polar substituent represented by R 3 is a carboxylate or a carboxylate bioisostere.
- Carboxylate bioisostere or “carboxy bioisostere” as used herein refers to a moiety that is expected to be negatively charged to a substantial degree at physiological pH.
- the carboxylate bioisostere is a moiety selected from the group consisting of:
- each R 7 is independently H or an optionally substituted member selected from the group consisting of C 1-10 alkyl, C 2-10 alkenyl, C 2-10 heteroalkyl, C 3-8 carbocyclic ring, and C 3-8 heterocyclic ring optionally fused to an additional optionally substituted carbocyclic or heterocyclic ring; or R 7 is a C 1-10 alkyl, C 2-10 alkenyl, or C 2-10 heteroalkyl substituted with an optionally substituted C 3-8 carbocyclic ring or C 3-8 heterocyclic ring.
- the polar substituent is selected from the group consisting of carboxylic acid, carboxylic ester, carboxamide, tetrazole, triazole, carboxymethanesulfonamide, oxadiazole, oxothiadiazole, thiazole, aminothiazole and hydroxythiazole.
- at least one R present is a carboxylic acid or a salt, or ester or a bioisostere thereof.
- at least one R 3 present is a carboxylic acid-containing substituent or a salt, ester or bioisostere thereof.
- the R 3 substituent may be a C1-C10 alkyl or C1-C10 alkenyl linked to a carboxylic acid (or salt, ester or bioisostere thereof), for example, and in some embodiments, the R 3 substituent is not -NHCOOCH 2 CH 3 .
- At least one of Z 1 -Z 4 and Z 5 -Z 8 is a nitrogen atom
- one or more ring nitrogen atoms can be positioned in the ring containing Z 1 -Z 4 or in the ring containing Z 5 -Z 8 such that each ring is independently an optionally substituted pyridine, pyrimidine or pyridazine ring.
- one or more ring nitrogen atoms within the ring containing Z 5 -Z 8 may be arranged as follows:
- each R 6A , R 6B , R 6C and R 6D independently is selected from R 6 substituents defined above with respect to compounds of Formula I, II, III or IV.
- no two adjacent Z 1 -Z 4 or Z 5 -Z 8 both are N.
- a polar substituent may be at any position on the ring containing Z 1 -Z 4 in Formula I, II, III or IV, and the ring may include one, two, three or four polar substituents.
- each of Z 1 -Z 4 may be CR 3 and one of the R 3 substituents may be a polar substituent (e.g., a carboxylate or carboxylic acid ester, or a tetrazole) arranged at any one of the positions in the ring containing Z 1 -Z 4 :
- R 3P is a polar substituent and each R 3A , R 3B , R 3C and R 3D independently is selected from R 3 substituents, as defined above with respect to compounds of Formula I, II, III or IV.
- R 4 is H.
- R 4 is H or CH 3 and R 5 is an optionally substituted 3-8 membered ring, which can be aromatic, nonaromatic, and carbocyclic or heterocyclic, or R is a C 1-10 alkyl group substituted with such an optionally substituted 3-8 membered ring.
- R 5 is an optionally substituted five-, six-, or seven-membered carbocyclic or heterocyclic ring, and sometimes is an optionally substituted phenyl ring.
- R 4 is H or CH 3 and R 5 is a phenyl substituted with one or more halogen (e.g., F, Cl) or acetylene substituents, which substituents sometimes are on the phenyl ring at the 3-position, 4-position or 5- position, or combinations thereof (e.g., the 3- and 5-positions).
- halogen e.g., F, Cl
- acetylene substituents which substituents sometimes are on the phenyl ring at the 3-position, 4-position or 5- position, or combinations thereof (e.g., the 3- and 5-positions).
- R 5 in certain embodiments is a C 1-2 alkyl substituted with an optionally substituted phenyl, pyridyl or morpholino ring substituent, or substituted with -NR 4 R 4 where R 4 is as defined above (e.g., R 5 may be -N(CH 3 ) 2 ).
- the polar group represented by R 3 in some embodiments is a carboxy, carboxyalkyl (e.g., carboxymethyl), tetrazole or amide (e.g., -CONH 2 ) substituent. In other embodiments, R 3 represents a carboxylate bioisostere.
- R 6 substituent in certain embodiments such as R 6B , sometimes is a -NR 4 R 5 substituent, such as a -NH-(C1-C6 alkyl) moiety (e.g., -NH-CH 3 ), for example.
- the compound has the structure of Formula I; R 4 is H or CH 3 ; R 5 is an optionally substituted five-, six-, or seven-membered carbocyclic or heterocyclic ring, and sometimes is an optionally substituted phenyl ring; and one R 3 is a carboxylic acid or a salt, an ester or a carboxylate bioisostere.
- the compound has the structure of Formula I; R 4 is H or CH 3 ; R 5 is an optionally substituted five-, six-, or seven-membered carbocyclic or heterocyclic ring, and sometimes is an optionally substituted phenyl ring; and one or two of Z 5 , Z 6 , Z 7 and Z 8 are N.
- each of Z 1 , Z 2 , Z 3 , and Z 4 is CR 3 , and at least one R 3 is H, or at least two R 3 are H. Often, at least one R 6 is H, or at least two R 6 are H.
- each Z 1 , Z 2 , Z 3 , Z 4 , Z 5 , Z 6 and Z 8 is CR 3 and Z 7 is nitrogen; or (ii) each Z 1 , Z 2 , Z 3 , Z 4 , Z 6 , Z 7 and Z 8 is CR 3 and Z 5 is nitrogen; or (iii) each Z 1 , Z 2 , Z 3 , Z 4 , Z 6 , and Z 8 is CR 3 and each of Z 5 and Z 7 is nitrogen.
- Each R 3 and/or each R 6 present in certain embodiments is hydrogen, except that at least one R 3 present is a polar substituent.
- each R 3A , R 3C , R 3D , R 6A , R 6B , R 6C and R 6D is H and R 3B is a polar substituent (e.g., carboxylate, carboxylic acid, tetrazole).
- R 3B is a polar substituent (e.g., carboxylate, carboxylic acid, tetrazole).
- each Z 1 , Z 2 , Z 3 , and Z 4 independently is N or CR 3 and none, one or two of Z 1 , Z 2 , Z 3 , and Z 4 is N; each R 3 , R 6A and R 6B independently is H or an optionally substituted C1-C8 alkyl, C2-C8 heteroalkyl, C2-C8 alkenyl, C2-C8 heteroalkenyl, C2-C8 alkynyl, C2-C8 heteroalkynyl, C1-C8 acyl, C2-C8 heteroacyl, C6-C10 aryl, C5-C12 heteroaryl, C7-C12 arylalkyl, or C6-C12 heteroarylalkyl group, or each R 3 , R 6A and R 6B independently is halo, OR, NR 2
- R 4 is H or optionally substituted member selected from the group consisting of Ci-C 6 alkyl, C2-C6 heteroalkyl, and C1-C6 acyl; each R is independently H or an optionally substituted member selected from the group consisting of C 1-10 alkyl, C 2-10 alkenyl, C 2-10 heteroalkyl, C 3-8 carbocyclic ring, and C 3-8 heterocyclic ring optionally fused to an additional optionally substituted carbocyclic or heterocyclic; or R 5 is a C 1-10 alkyl, C 2-10 alkenyl, or C 2-10 heteroalkyl substituted with an optionally substituted C 3-8 carbocyclic ring or C 3-8 heterocyclic ring; and in each -NR 4 R 5 , R 4 and R 5 together with N may form an optionally substituted 3-8 membered ring, which may optionally contain an additional heteroatom selected from N, O and S as a ring member; provided that if R 5 in Formula IV is phenyl, substitute
- each of Z 1 , Z 2 , Z 3 , and Z 4 is CR 3 , and at least one R 3 is H, or at least two R 3 are H.
- at least one of R 6A and R 6B is H, and sometimes each of R 6A and R 6B is H.
- each R 3 and/or each of R 6A and R 6B present is H, except that at least one R 3 present is a polar substituent.
- each R 3A , R 3C , R 3D , R 6A and R 6B is H and R 3B is a polar substituent (e.g., carboxylate bioisostere, carboxylic acid, tetrazole).
- R 3B is a polar substituent (e.g., carboxylate bioisostere, carboxylic acid, tetrazole).
- R 4 is H or CH 3 and R is an optionally substituted five-, six- or seven-membered carbocyclic or heterocyclic ring (e.g., optionally substituted phenyl ring).
- R 4 is H or CH 3 and R 5 is a phenyl ring substituted with one or more halogen (e.g., F, Cl) or acetylene substituents, which substituents sometimes are at the 3-position, 4- position or 5-position, or a combination thereof (e.g., the 3- and 5-positions).
- halogen e.g., F, Cl
- acetylene substituents which substituents sometimes are at the 3-position, 4- position or 5-position, or a combination thereof (e.g., the 3- and 5-positions).
- R in certain embodiments is a Ci_ 3 alkyl substituted with an optionally substituted phenyl, pyridyl, morpholino or pyrrolyl substituent, or a C 1-3 alkyl substituted with a hydroxyl substituent or substituted with a substituent -NR 4 R 4 , where R 4 is as defined above (e.g., R 5 can be - N(CH 3 ) 2 ).
- R 6 substituent in certain embodiments, such as R 6A or R 6B sometimes is a - NR 4 R 5 substituent, such as a -NH-(C1-Co alkyl) moiety (e.g., -NH-CH 3 ), for example.
- R 3 is a polar substituent, such as a polar substituent described above (e.g., carboxylic acid, carboxylate, tetrazole).
- R 4 and R 5 are not both hydrogen, and independently are H, -Y 0 or -LY 1 , where Y 0 is an optionally substituted 5-membered ring or optionally substituted 6-membered ring (e.g., heterocyclic ring or carbocyclic ring each being aryl or non-aryl), Y 1 is an optionally substituted 5-membered aryl ring or optionally substituted 6-membered aryl ring, and L is a C1-C20 alkyl linker or C1-C20 alkylene linker.
- Y 0 is an optionally substituted 5-membered ring or optionally substituted 6-membered ring (e.g., heterocyclic ring or carbocyclic ring each being aryl or non-aryl)
- Y 1 is an optionally substituted 5-membered aryl ring or optionally substituted 6-membered aryl ring
- L is a C1-C20 alkyl linker or C
- each Z 1 , Z 2 , Z 3 , and Z 4 is N or CR 3 and none, one or two of Z 1 , Z 2 , Z 3 , and Z 4 is N; each R 3 and R 6 is independently H or an optionally substituted C1-C8 alkyl, C2-C8 heteroalkyl, C2-C8 alkenyl, C2-C8 heteroalkenyl, C2-C8 alkynyl, C2-C8 heteroalkynyl, C1-C8 acyl, C2-C8 heteroacyl, C6-C10 aryl, C5-C12 heteroaryl, C7-C12 arylalkyl, or C6-C12 heteroarylalkyl group, or each R 3 and R 6 can be halo, OR, NR 2 , NROR,
- R 4 is H or optionally substituted member selected from the group consisting of Ci-C ⁇ alkyl, C2-C6 heteroalkyl, and C1-C6 acyl; each R 5 is independently H or an optionally substituted member selected from the group consisting of C 1-10 alkyl, C 2-10 alkenyl, C 2-10 heteroalkyl, C 3-8 carbocyclic ring, and C 3-8 heterocyclic ring optionally fused to an additional optionally substituted carbocyclic or heterocyclic; or R 5 is a C 1-10 alkyl, C 2-10 alkenyl, or C 2-10 heteroalkyl substituted with an optionally substituted C 3-8 carbocyclic ring or C 3-8 heterocyclic ring; and in each -NR 4 R 5 , R 4 and R 5 together with N may form an optionally substituted 3-8 membered ring, which may optionally contain an additional heteroatom selected from N, O and S as a ring member.
- Embodiments described with respect to compounds of Formulae I, II, III, IV, V, VI, VII and VIII also may be applied to compounds of Formulae IX, X, XI and XII.
- each of Z 1 , Z 2 , Z 3 , and Z 4 is CR 3 , and at least one R 3 is H, or at least two R 3 are H.
- R 6 often is H, and in certain embodiments, each R 6 and R 3 present is H, except that at least one R 3 present is a polar substituent.
- each R 3A , R 3C , R 3D and R 6 is H and R 3B is a polar substituent (e.g., carboxylate, carboxylic acid, tetrazole).
- R 4 is H or CH 3 and R is an optionally substituted five-, six- or seven-membered carbocyclic or heterocyclic ring (e.g., optionally substituted phenyl ring).
- R 4 is H or CH 3 and R is a phenyl ring substituted with one or more halogen (e.g., F, Cl) or acetylene substituents, which substituents sometimes are at the 3-position, A- position or 5-position, or a combination thereof (e.g., the 3- and 5-positions).
- R in certain embodiments is a Ci_ 3 alkyl substituted with an optionally substituted phenyl, pyridyl, morpholino or pyrrolyl substituent, or a C 1-3 alkyl substituted with a hydroxyl substituent or substituted with a -NR 4 R 4 (e.g., -N(CH 3 ) 2 ) substituent.
- R 6 in certain embodiments sometimes is a -NR 4 R 5 substituent, such as a -NH-(C1-C6 alkyl) moiety (e.g., -NH-CH 3 ), for example.
- Z 5 is N or CR 6A ; each R 6A , R 6B , R 6C and R 8 independently is H or an optionally substituted C1-C8 alkyl, C2-C8 heteroalkyl, C2-C8 alkenyl, C2-C8 heteroalkenyl, C2-C8 alkynyl, C2-C8 heteroalkynyl, C1-C8 acyl, C2-C8 heteroacyl, C6-C10 aryl, C5-C12 heteroaryl, C7-C12 arylalkyl, or C6-C12 heteroarylalkyl group, or each R 6A , R 6B , R 6C and R 8 independently is halo, CF 3 , CFN, OR, NR 2 , NROR, NRNR 2 , SR, SOR, SO 2 R, SO 2 NR 2 , NRSO 2 R, NRCONR 2 , NRCOOR, NRCOR, CN, COOR, carboxy biois
- R 9 is independently an optionally substituted C1-C8 alkyl, C2-C8 heteroalkyl, C2-C8 alkenyl, C2-C8 heteroalkenyl, C2-C8 alkynyl, C2-C8 heteroalkynyl, C1-C8 acyl, C2-C8 heteroacyl, C6-C10 aryl, C5-C12 heteroaryl, C7-C12 arylalkyl, or C6-C12 heteroarylalkyl group, or
- R 9 is independently halo, OR, NR 2 , NROR, NRNR 2 , SR, SOR, SO 2 R, SO 2 NR 2 , NRSO 2 R, NRCONR 2 , NRCOOR, NRCOR, CN, COOR, CONR 2 , OOCR, COR, or NO 2 , wherein each R is independently H or C1-C8 alkyl, C2-C8 heteroalkyl, C2-C8 alkenyl, C2-C8 heteroalkenyl, C2-C8 alkynyl, C2-C8 heteroalkynyl, C1-C8 acyl, C2-C8 heteroacyl, C6-C10 aryl, C5-C10 heteroaryl, C7-C12 arylalkyl, or C6-C12 heteroarylalkyl, and wherein two R on the same atom or on adjacent atoms can be linked to form a 3-8 membered ring, optionally containing one or more N, O
- Z 5 is N.
- R 8 is a caboxy moiety, such as a carboxylate or carboxylic acid.
- R 9 is selected from -C ⁇ CR, -C ⁇ CH, -CH 3 , - CH 2 CH 3 , -CF 3 , -CFN, -C ⁇ N, -OR or halogen. In some embodiments R 9 is selected from halogen, -C ⁇ CR or -C ⁇ CH.
- R 9 is selected from halogen or -C ⁇ CH, and in some embodiments R 9 is halogen, is chloro, is bromo or is -C ⁇ CH.
- a pharmaceutical composition comprising a compound described herein and a pharmaceutically acceptable carrier. Pharmaceutical compositions can be utilized in treatments described herein.
- identifying a candidate molecule that interacts with a CK2 or PARP protein comprise: contacting a composition containing a CK2 or PARP protein and a compound described herein with a candidate molecule under conditions in which the compound and the protein interact, and determining whether the amount of the compound that interacts with the protein is modulated relative to a control interaction between the compound and the protein without the candidate molecule, whereby a candidate molecule that modulates the amount of the compound interacting with the protein relative to the control interaction is identified as a candidate molecule that interacts with the protein.
- the protein is a CK2 protein, such as a CK2 protein comprising the amino acid sequence of SEQ ID NO: 1, 2 or 3 or a substantially identical variant thereof, for example.
- SEQ ID NO: 1 NP 001886; casein kinase II alpha 1 subunit isoform a [Homo sapiens]
- SEQ ID NO: 2 (NP 808227; casein kinase II alpha 1 subunit isoform a [Homo sapiens])
- SEQ ID NO: 3 (NP 808228; casein kinase II alpha 1 subunit isoform b [Homo sapiens])
- the protein is a PARP protein, such as a PARP protein comprising the amino acid sequence of SEQ ID NO: 4 or a substantially identical variant thereof, for example.
- SEQ ID NO: 4 (NP 001609; poly (ADP-ribose) polymerase family, member 1 [Homo sapiens])
- the protein is in a cell or in a cell-free system.
- the protein, the compound or the molecule in some embodiments is in association with a solid phase.
- the interaction between the compound and the protein is detected via a detectable label, where in some embodiments the protein comprises a detectable label and in certain embodiments the compound comprises a detectable label. The interaction between the compound and the protein sometimes is detected without a detectable label.
- Also provided are methods for modulating the activity of a CK2 protein or PARP protein which comprise contacting a system comprising the protein with a compound described herein in an amount effective for modulating the activity of the protein.
- the activity of the protein is inhibited, and sometimes the protein is a CK2 protein, such as a CK2 protein comprising the amino acid sequence of SEQ ID NO: 1, 2 or 3 or a substantially identical variant thereof, for example.
- the protein is a PARP protein, such as a PARP protein comprising the amino acid sequence of SEQ ID NO: 4 or a substantially identical variant thereof, for example.
- the system is a cell, and in other embodiments the system is a cell-free system.
- the protein or the compound may be in association with a solid phase in certain embodiments.
- a cell line such as a cancer cell line (e.g., breast cancer, prostate cancer, pancreatic cancer, lung cancer, hemopoietic cancer, colorectal cancer, skin cancer, ovary cancer cell line), for example.
- the cancer cell line is a breast cancer, prostate cancer or pancreatic cancer cell line.
- the cells sometimes are in a tissue, can be in a subject, at times are in a tumor, and sometimes are in a tumor in a subject.
- the method further comprises inducing cell apoptosis.
- Cells sometimes are from a subject having macular degeneration.
- methods for treating a condition related to aberrant cell proliferation which comprise administering a compound described herein to a subject in need thereof in an amount effective to treat the cell proliferative condition.
- the cell proliferative condition is a tumor-associated cancer.
- the cancer sometimes is of the breast, prostate, pancreas, lung, colorectum, skin, or ovary.
- the cell proliferative condition is a non-tumor cancer, such as a hematopoietic cancer, for example.
- the cell proliferative condition is macular degeneration in some embodiments.
- kits for treating cancer or an inflammatory disorder in a subject in need of such treatment comprising: administering to the subject a therapeutically effective amount of a therapeutic agent as described herein; and administering to the subject a molecule that inhibits PARP or CK2 in an amount that is effective to enhance a desired effect of the therapeutic agent.
- the therapeutic agent sometimes is a compound of formula TA1-1, TA2, TA3-1, TA4-1, TA5-1 or TA6-1 as described herein, or a pharmaceutically acceptable salt of one of these compounds.
- the molecule that inhibits PARP or CK2 is a compound of Formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI or XII as described herein, or a pharmaceutically acceptable salt thereof.
- the molecule that inhibits PARP or CK2 is a known compound shown above, or a compound in one of the Tables provided herein, or a pharmaceutically acceptable salt of one of these compounds.
- the desired effect of the therapeutic agent that is enhanced by the molecule that inhibits PARP or CK2 is a reduction in cell proliferation.
- the desired effect of the therapeutic agent that is enhanced by the molecule that inhibits PARP or CK2 is an increase in apoptosis in at least one type of cell.
- the therapeutic agent in certain embodiments is:
- the therapeutic agent and the molecule that inhibits PARP or CK2 are administered at substantially the same time.
- the therapeutic agent and molecule that inhibits PARP or CK2 sometimes are used concurrently by the subject.
- the therapeutic agent and the molecule that inhibits PARP or CK2 are combined into one pharmaceutical composition in certain embodiments.
- Some embodiments are directed to a pharmaceutical composition comprising a therapeutic agent of any of formulas TA1-1, TA2, TA3-1, TA4-1, TA5-1 or TA6 admixed with a molecule that inhibits PARP or CK2, or a pharmaceutically acceptable salt thereof.
- the molecule that inhibits PARP or CK2 is a PARP inhibitor and is a known compound shown above, or is GPI 15427, GPI 16539.
- the molecule that inhibits PARP or CK2 is a compound of Formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI or XII as described herein, or a pharmaceutically acceptable salt thereof.
- the therapeutic agent is a compound of formula TA2 or a pharmaceutically acceptable salt thereof.
- a therapeutic composition in certain embodiments comprises a therapeutically effective amount of a therapeutic agent of the formula TA2:
- a PARP inhibitor or a pharmaceutically acceptable salt thereof or a specific isomer or mixture of isomers thereof, admixed with an amount of a PARP inhibitor or a pharmaceutically acceptable salt of a PARP inhibitor, wherein the PARP inhibitor is selected from the group consisting of GPI 15427, GPI 16539, and the known compounds shown above; and where the amount of the PARP inhibitor or the pharmaceutically acceptable salt of a PARP inhibitor is an amount that is effective to enhance a desired effect of the therapeutic agent.
- compositions comprising a compound described herein and an isolated protein.
- the protein sometimes is a CK2 protein, such as a CK2 protein comprising the amino acid sequence of SEQ ID NO: 1, 2 or 3 or a substantially identical variant thereof, for example.
- the protein is a PARP protein, such as a PARP protein comprising the amino acid sequence of SEQ ID NO: 4 or a substantially identical variant thereof, for example.
- Certain compositions comprise a compound described herein in combination with a cell.
- the cell may be from a cell line, such as a cancer cell line. In the latter embodiments, the cancer cell line is sometimes a breast cancer, prostate cancer, pancreatic cancer, lung cancer, hemopoietic cancer, colorectal cancer, skin cancer, ovary cancer cell line.
- Figure 1 depicts assay data showing inhibition of CK2 activity.
- Figures 2A and 2B show mean plasma concentrations of compounds described herein over time after intravenous and oral administration to ICR mice.
- Figures 3A and 3B show tumor volume over time and body weight over time, respectively, in tumor-bearing xenograft animals administered a compound described herein.
- Figures 3C and 3D illustrate effects of the compound on tumors in individual animals.
- Figures 4A and 4B show tumor volume over time and body weight over time, respectively, in tumor-bearing xenograft animals administered a compound described herein.
- Compounds of Formulae I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV and XVI can exert biological activities that include, but are not limited to, inhibiting cell proliferation, modulating protein kinase activity and modulating polymerase activity.
- Compounds of such Formulae can modulate CK2 activity and/or PARP activity, for example. Such compounds therefore can be utilized in multiple applications by a person of ordinary skill in the art.
- compounds described herein may find uses that include, but are not limited to, (i) modulation of protein kinase activity (e.g., CK2 activity), (ii) modulation of polymerase activity (e.g., PARP activity), (iii) modulation of cell proliferation, (iv) modulation of apoptosis, and (v) treatments of cell proliferation related disorders (e.g., administration alone or co-administration with another molecule).
- protein kinase activity e.g., CK2 activity
- modulation of polymerase activity e.g., PARP activity
- modulation of cell proliferation e.g., iv
- modulation of apoptosis e.g., apoptosis
- the group takes up two available valences, so the total number of substituents that may be included is reduced according to the number of available valences.
- the compounds of the invention often have ionizable groups so as to be capable of preparation as salts.
- a pharmaceutically acceptable salt may also be used.
- These salts may be acid addition salts involving inorganic or organic acids or the salts may, in the case of acidic forms of the compounds of the invention be prepared from inorganic or organic bases.
- the compounds are prepared or used as pharmaceutically acceptable salts prepared as addition products of pharmaceutically acceptable acids or bases.
- Suitable pharmaceutically acceptable acids and bases are well-known in the art, such as hydrochloric, sulphuric, hydrobromic, acetic, lactic, citric, or tartaric acids for forming acid addition salts, and potassium hydroxide, sodium hydroxide, ammonium hydroxide, caffeine, various amines, and the like for forming basic salts. Methods for preparation of the appropriate salts are well- established in the art.
- the compounds may contain both an acidic and a basic functional group, in which case they may have two ionized groups and yet have no net charge.
- the compounds of the invention contain one or more chiral centers.
- the invention includes each of the isolated stereoisomeric forms as well as mixtures of stereoisomers in varying degrees of chiral purity, including racemic mixtures. It also encompasses the various diastereomers and tautomers that can be formed.
- the compounds of the invention may also exist in more than one tautomeric form; the depiction herein of one tautomer is for convenience only, and is also understood to encompass other tautomers of the form shown.
- alkyl straight-chain, branched-chain and cyclic monovalent hydrocarbyl radicals, and combinations of these, which contain only C and H when they are unsubstituted. Examples include methyl, ethyl, isobutyl, cyclohexyl, cyclopentylethyl, 2-propenyl, 3-butynyl, and the like.
- the total number of carbon atoms in each such group is sometimes described herein, e.g., when the group can contain up to ten carbon atoms it can be represented as 1-10C or as C1-C10 or C1-10.
- heteroatoms N, O and S typically
- the numbers describing the group though still written as e.g. C1-C6, represent the sum of the number of carbon atoms in the group plus the number of such heteroatoms that are included as replacements for carbon atoms in the backbone of the ring or chain being described.
- the alkyl, alkenyl and alkynyl substituents of the invention contain M0C (alkyl) or 2- 10C (alkenyl or alkynyl). Preferably they contain 1-8C (alkyl) or 2-8C (alkenyl or alkynyl). Sometimes they contain 1-4C (alkyl) or 2-4C (alkenyl or alkynyl).
- a single group can include more than one type of multiple bond, or more than one multiple bond; such groups are included within the definition of the term "alkenyl" when they contain at least one carbon-carbon double bond, and are included within the term "alkynyl" when they contain at least one carbon-carbon triple bond.
- Alkyl, alkenyl and alkynyl groups are often optionally substituted to the extent that such substitution makes sense chemically.
- Alkyl, alkenyl and alkynyl groups can also be substituted by C1- C8 acyl, C2-C8 heteroacyl, C6-C10 aryl or C5-C10 heteroaryl, each of which can be substituted by the substituents that are appropriate for the particular group.
- R a of -C ⁇ C-R a is H or Me.
- Heteroalkyl “heteroalkenyl”, and “heteroalkynyl” and the like are defined similarly to the corresponding hydrocarbyl (alkyl, alkenyl and alkynyl) groups, but the 'hetero' terms refer to groups that contain 1-3 O, S or N heteroatoms or combinations thereof within the backbone residue; thus at least one carbon atom of a corresponding alkyl, alkenyl, or alkynyl group is replaced by one of the specified heteroatoms to form a heteroalkyl, heteroalkenyl, or heteroalkynyl group.
- heteroforms of alkyl, alkenyl and alkynyl groups are generally the same as for the corresponding hydrocarbyl groups, and the substituents that may be present on the heteroforms are the same as those described above for the hydrocarbyl groups.
- substituents that may be present on the heteroforms are the same as those described above for the hydrocarbyl groups.
- such groups do not include more than two contiguous heteroatoms except where an oxo group is present on N or S as in a nitro or sulfonyl group.
- alkyl as used herein includes cycloalkyl and cycloalkylalkyl groups
- cycloalkyl may be used herein to describe a carbocyclic non-aromatic group that is connected via a ring carbon atom
- cycloalkylalkyl may be used to describe a carbocyclic non-aromatic group that is connected to the molecule through an alkyl linker.
- heterocyclyl may be used to describe a non-aromatic cyclic group that contains at least one heteroatom as a ring member and that is connected to the molecule via a ring atom, which may be C or N; and “heterocyclylalkyl” may be used to describe such a group that is connected to another molecule through a linker.
- the sizes and substituents that are suitable for the cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl groups are the same as those described above for alkyl groups. As used herein, these terms also include rings that contain a double bond or two, as long as the ring is not aromatic.
- acyl encompasses groups comprising an alkyl, alkenyl, alkynyl, aryl or arylalkyl radical attached at one of the two available valence positions of a carbonyl carbon atom
- heteroacyl refers to the corresponding groups wherein at least one carbon other than the carbonyl carbon has been replaced by a heteroatom chosen from N, O and S.
- Acyl and heteroacyl groups are bonded to any group or molecule to which they are attached through the open valence of the carbonyl carbon atom. Typically, they are C1- C8 acyl groups, which include formyl, acetyl, pivaloyl, and benzoyl, and C2-C8 heteroacyl groups, which include methoxyacetyl, ethoxycarbonyl, and 4-pyridinoyl.
- the hydrocarbyl groups, aryl groups, and heteroforms of such groups that comprise an acyl or heteroacyl group can be substituted with the substituents described herein as generally suitable substituents for each of the corresponding component of the acyl or heteroacyl group.
- Aromatic moiety or "aryl” moiety refers to a monocyclic or fused bicyclic moiety having the well-known characteristics of aromaticity; examples include phenyl and naphthyl.
- heteromatic and “heteroaryl” refer to such monocyclic or fused bicyclic ring systems which contain as ring members one or more heteroatoms selected from O, S and N. The inclusion of a heteroatom permits aromaticity in 5-membered rings as well as 6-membered rings.
- Typical heteroaromatic systems include monocyclic C5-C6 aromatic groups such as pyridyl, pyrimidyl, pyrazinyl, thienyl, furanyl, pyrrolyl, pyrazolyl, thiazolyl, oxazolyl, and imidazolyl and the fused bicyclic moieties formed by fusing one of these monocyclic groups with a phenyl ring or with any of the heteroaromatic monocyclic groups to form a C8-C10 bicyclic group such as indolyl, benzimidazolyl, indazolyl, benzotriazolyl, isoquinolyl, quinolyl, benzothiazolyl, benzofuranyl, pyrazolopyridyl, quinazolinyl, quinoxalinyl, cinnolinyl, and the like.
- monocyclic C5-C6 aromatic groups such as pyridyl, pyrimidy
- any monocyclic or fused ring bicyclic system which has the characteristics of aromaticity in terms of electron distribution throughout the ring system is included in this definition. It also includes bicyclic groups where at least the ring which is directly attached to the remainder of the molecule has the characteristics of aromaticity.
- the ring systems contain 5-12 ring member atoms.
- the monocyclic heteroaryls contain 5-6 ring members, and the bicyclic heteroaryls contain 8-10 ring members.
- Aryl and heteroaryl moieties may be substituted with a variety of substituents including C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C5-C12 aryl, C1-C8 acyl, and heteroforms of these, each of which can itself be further substituted; other substituents for aryl and heteroaryl moieties include halo, OR, NR 2 , SR, SO 2 R, SO 2 NR 2 , NRSO 2 R, NRCONR 2 , NRCOOR, NRCOR, CN, C ⁇ CR, COOR, CONR 2 , OOCR, COR, and NO 2 , wherein each R is independently H, C1-C8 alkyl, C2-C8 heteroalkyl, C2-C8 alkenyl, C2-C8 heteroalkenyl, C2- C8 alkynyl, C2-C8 heteroalkynyl, C6-C10 aryl, C
- an arylalkyl substituent may be substituted on the aryl portion with substituents described herein as typical for aryl groups, and it may be further substituted on the alkyl portion with substituents described herein as typical or suitable for alkyl groups.
- arylalkyl and “heteroarylalkyl” refer to aromatic and heteroaromatic ring systems which are bonded to their attachment point through a linking group such as an alkylene, including substituted or unsubstituted, saturated or unsaturated, cyclic or acyclic linkers.
- the linker is C1-C8 alkyl or a hetero form thereof.
- These linkers may also include a carbonyl group, thus making them able to provide substituents as an acyl or heteroacyl moiety.
- An aryl or heteroaryl ring in an arylalkyl or heteroarylalkyl group may be substituted with the same substituents described above for aryl groups.
- an arylalkyl group includes a phenyl ring optionally substituted with the groups defined above for aryl groups and a C1-C4 alkylene that is unsubstituted or is substituted with one or two C1-C4 alkyl groups or heteroalkyl groups, where the alkyl or heteroalkyl groups can optionally cyclize to form a ring such as cyclopropane, dioxolane, or oxacyclopentane.
- a heteroarylalkyl group preferably includes a C5-C6 monocyclic heteroaryl group that is optionally substituted with the groups described above as substituents typical on aryl groups and a C1-C4 alkylene that is unsubstituted or is substituted with one or two C1-C4 alkyl groups or heteroalkyl groups, or it includes an optionally substituted phenyl ring or C5- C6 monocyclic heteroaryl and a C1-C4 hetero alkylene that is unsubstituted or is substituted with one or two C1-C4 alkyl or heteroalkyl groups, where the alkyl or heteroalkyl groups can optionally cyclize to form a ring such as cyclopropane, dioxolane, or oxacyclopentane.
- substituents may be on either the alkyl or heteroalkyl portion or on the aryl or heteroaryl portion of the group.
- the substituents optionally present on the alkyl or heteroalkyl portion are the same as those described above for alkyl groups generally; the substituents optionally present on the aryl or heteroaryl portion are the same as those described above for aryl groups generally.
- Arylalkyl groups as used herein are hydrocarbyl groups if they are unsubstituted, and are described by the total number of carbon atoms in the ring and alkylene or similar linker.
- a benzyl group is a C7-arylalkyl group
- phenylethyl is a C8- arylalkyl.
- Heteroarylalkyl refers to a moiety comprising an aryl group that is attached through a linking group, and differs from “arylalkyl” in that at least one ring atom of the aryl moiety or one atom in the linking group is a heteroatom selected from N, O and S.
- the heteroarylalkyl groups are described herein according to the total number of atoms in the ring and linker combined, and they include aryl groups linked through a heteroalkyl linker; heteroaryl groups linked through a hydrocarbyl linker such as an alkylene; and heteroaryl groups linked through a heteroalkyl linker.
- C7- heteroarylalkyl would include pyridylmethyl, phenoxy, and N-pyrrolylmethoxy.
- Alkylene refers to a divalent hydrocarbyl group; because it is divalent, it can link two other groups together. Typically it refers to -(CH 2 ),,- where n is 1-8 and preferably n is 1-4, though where specified, an alkylene can also be substituted by other groups, and can be of other lengths, and the open valences need not be at opposite ends of a chain. Thus -CH(Me)- and -C(Me) 2 - may also be referred to as alkylenes, as can a cyclic group such as cyclopropan-l,l-diyl. Where an alkylene group is substituted, the substituents include those typically present on alkyl groups as described herein.
- any alkyl, alkenyl, alkynyl, acyl, or aryl or arylalkyl group or any heteroform of one of these groups that is contained in a substituent may itself optionally be substituted by additional substituents.
- the nature of these substituents is similar to those recited with regard to the primary substituents themselves if the substituents are not otherwise described.
- R 7 is alkyl
- this alkyl may optionally be substituted by the remaining substituents listed as embodiments for R 7 where this makes chemical sense, and where this does not undermine the size limit provided for the alkyl per se; e.g., alkyl substituted by alkyl or by alkenyl would simply extend the upper limit of carbon atoms for these embodiments, and is not included.
- each such alkyl, alkenyl, alkynyl, acyl, or aryl group may be substituted with a number of substituents according to its available valences; in particular, any of these groups may be substituted with fluorine atoms at any or all of its available valences, for example.
- Heteroform refers to a derivative of a group such as an alkyl, aryl, or acyl, wherein at least one carbon atom of the designated carbocyclic group has been replaced by a heteroatom selected from N, O and S.
- the heteroforms of alkyl, alkenyl, alkynyl, acyl, aryl, and arylalkyl are heteroalkyl, heteroalkenyl, heteroalkynyl, heteroacyl, heteroaryl, and heteroarylalkyl, respectively. It is understood that no more than two N, O or S atoms are ordinarily connected sequentially, except where an oxo group is attached to N or S to form a nitro or sulfonyl group.
- Halo as used herein includes fluoro, chloro, bromo and iodo. Fluoro and chloro are often preferred.
- Amino refers to NH 2 , but where an amino is described as “substituted” or “optionally substituted”, the term includes NR' R" wherein each R' and R" is independently H, or is an alkyl, alkenyl, alkynyl, acyl, aryl, or arylalkyl group or a heteroform of one of these groups, and each of the alkyl, alkenyl, alkynyl, acyl, aryl, or arylalkyl groups or heteroforms of one of these groups is optionally substituted with the substituents described herein as suitable for the corresponding group.
- R' and R" are linked together to form a 3-8 membered ring which may be saturated, unsaturated or aromatic and which contains 1-3 heteroatoms independently selected from N, O and S as ring members, and which is optionally substituted with the substituents described as suitable for alkyl groups or, if NR' R" is an aromatic group, it is optionally substituted with the substituents described as typical for heteroaryl groups.
- carbocycle refers to a cyclic compound containing only carbon atoms in the ring, whereas a “heterocycle” refers to a cyclic compound comprising a heteroatom.
- the carbocyclic and heterocyclic structures encompass compounds having monocyclic, bicyclic or multiple ring systems.
- heteroatom refers to any atom that is not carbon or hydrogen, such as nitrogen, oxygen or sulfur.
- heterocycles include but are not limited to tetrahydrofuran, 1,3 dioxolane, 2,3 dihydrofuran, pyran, tetrahydropyran, benzofuran, isobenzofuran, 1,3 dihydro isobenzofuran, isoxazole, 4,5 dihydroisoxazole, piperidine, pyrrolidine, pyrrolidin 2 one, pyrrole, pyridine, pyrimidine, octahydro pyrrolo[3,4 b]pyridine, piperazine, pyrazine, morpholine, thiomorpholine, imidazole, imidazolidine 2,4 dione, 1 ,3 dihydrobenzimidazol 2 one, indole, thiazole, benzothiazole, thiadiazole, thiophene, tetrahydro thiophene 1,1 dioxide, diazepine, triazole,
- inorganic substituent refers to substituents that do not contain carbon or contain carbon bound to elements other than hydrogen (e.g., elemental carbon, carbon monoxide, carbon dioxide, and carbonate).
- inorganic substituents include but are not limited to nitro, halogen, azido, cyano, sulfonyls, sulfinyls, sulfonates, phosphates, etc.
- a candidate molecule or compound described herein may be in a therapeutically effective amount in a formulation or medicament, which is an amount that can lead to a biological effect, such as apoptosis of certain cells (e.g., cancer cells), reduction of proliferation of certain cells, or lead to ameliorating, alleviating, lessening, or removing symptoms of a disease or condition, for example.
- the terms also can refer to reducing or stopping a cell proliferation rate (e.g., slowing or halting tumor growth) or reducing the number of proliferating cancer cells (e.g., removing part or all of a tumor).
- microorganism examples include but are not limited to virus, bacterium and fungus.
- apoptosis refers to an intrinsic cell self-destruction or suicide program.
- cells undergo a cascade of events including cell shrinkage, blebbing of cell membranes and chromatic condensation and fragmentation. These events culminate in cell conversion to clusters of membrane-bound particles (apoptotic bodies), which are thereafter engulfed by macrophages.
- the invention in part provides pharmaceutical compositions comprising at least one compound within the scope of the invention as described herein, and methods of using compounds described herein.
- the invention in part provides methods for identifying a candidate molecule that interacts with a CK2 or PARP protein, which comprises contacting a composition containing a CK2 or PARP protein and a molecule described herein with a candidate molecule and determining whether the amount of the molecule described herein that interacts with the protein is modulated, whereby a candidate molecule that modulates the amount of the molecule described herein that interacts with the protein is identified as a candidate molecule that interacts with the protein.
- Also provided are methods for modulating the activity of a CK2 protein or PARP protein which comprises contacting a system comprising the protein with a compound described herein in an amount effective for modulating (e.g., inhibiting) the activity of the protein.
- the system in such embodiments can be a cell-free system or a system comprising cells.
- methods for reducing cell proliferation, and optionally inducing apoptosis which comprises contacting cells with a compound described herein in an amount effective to reduce proliferation of the cells.
- the cells in such embodiments can be in a cell line, in a tissue or in a subject (e.g., a research animal or human).
- compositions comprising a compound described herein in combination with a protein or cell, such as an isolated protein (e.g., isolated CK2 or other serine-threonine protein kinase protein or PARP protein) or a cell in a cell line (e.g., HCT-116 cell line).
- a protein or cell such as an isolated protein (e.g., isolated CK2 or other serine-threonine protein kinase protein or PARP protein) or a cell in a cell line (e.g., HCT-116 cell line).
- Serine-threonine protein kinases catalyze the transfer of a gamma phosphate from adenosine triphosphate to a serine or threonine amino acid in a peptide or protein substrate.
- methods which comprise contacting a system comprising a serine- threonine protein kinase protein with a compound described herein in an amount effective for modulating (e.g., inhibiting) the activity of the protein.
- the activity of the serine-threonine protein kinase is the catalytic activity of the protein (e.g., catalyzing the transfer of a gamma phosphate from adenosine triphosphate to a peptide or protein substrate).
- methods for identifying a candidate molecule that interacts with a serine-threonine protein kinase comprise: contacting a composition containing a serine-threonine protein kinase and a compound described herein with a candidate molecule under conditions in which the compound and the protein interact, and determining whether the amount of the compound that interacts with the protein is modulated relative to a control interaction between the compound and the protein without the candidate molecule, whereby a candidate molecule that modulates the amount of the compound interacting with the protein relative to the control interaction is identified as a candidate molecule that interacts with the protein.
- Systems in such embodiments can be a cell-free system or a system comprising cells (e.g., in vitro).
- the protein, the compound or the molecule in some embodiments is in association with a solid phase.
- the interaction between the compound and the protein is detected via a detectable label, where in some embodiments the protein comprises a detectable label and in certain embodiments the compound comprises a detectable label.
- the interaction between the compound and the protein sometimes is detected without a detectable label.
- the serine-threonine protein kinase can be from any source, such as a mammal, ape or human, for example.
- Examples of serine-threonine protein kinases that can be inhibited by compounds disclosed herein include without limitation human versions of CK2, CK2 ⁇ 2, Pim-1, CDK1/cyclinB, c-RAF, Mer, MELK, DYRK2, Flt3, Flt3 (D835Y), Flt4, HIPK3, HIPK2, ZIPK and ZIPK.
- a serine-threonine protein kinase sometimes is a member of a sub-family containing one or more of the following amino acids at positions corresponding to those listed in human CK2: leucine at position 45, methionine at position 163 and isoleucine at position 174.
- Examples of such protein kinases include without limitation human versions of CK2, STK10, HIPK2, HIPK3, DAPK3, DYK2 and PIM-1. Nucleotide and amino acid sequences for serine-threonine protein kinases and reagents are publicly available (e.g., World Wide Web URLs ncbi.nlm.nih.gov/sites/entrez/ and Invitrogen.com) .
- the invention also in part provides methods for treating a condition related to aberrant cell proliferation.
- methods of treating a cell proliferative condition in a subject which comprises administering a compound described herein to a subject in need thereof in an amount effective to treat the cell proliferative condition.
- the subject may be a research animal (e.g., rodent, dog, cat, monkey), optionally containing a tumor such as a xenograft tumor (e.g., human tumor), for example, or may be a human.
- a cell proliferative condition sometimes is a tumor or non-tumor cancer, including but not limited to, cancers of the colorectum, breast, lung, liver, pancreas, lymph node, colon, prostate, brain, head and neck, skin, liver, kidney, blood and heart (e.g., leukemia, lymphoma, carcinoma).
- cancers of the colorectum, breast, lung, liver, pancreas, lymph node, colon, prostate, brain, head and neck, skin, liver, kidney, blood and heart e.g., leukemia, lymphoma, carcinoma.
- methods of treating pain in a subject which comprise administering a compound described herein to a subject in need thereof in an amount effective to treat the pain.
- methods of treating inflammation in a subject which comprises administering a compound described herein to a subject in need thereof in an amount effective to treat the inflammation.
- the subject may be a research animal (e.g., rodent, dog, cat, monkey), for example, or may be a human.
- Conditions associated with inflammation and pain include without limitation acid reflux, heartburn, acne, allergies and sensitivities, Alzheimer's disease, asthma, atherosclerosis, bronchitis, carditis, celiac disease, chronic pain, Crohn's disease, cirrhosis, colitis, dementia, dermatitis, diabetes, dry eyes, edema, emphysema, eczema, fibromyalgia, gastroenteritis, gingivitis, heart disease, hepatitis, high blood pressure, insulin resistance, interstitial cystitis, joint pain/arthritis/rheumatoid arthritis, metabolic syndrome (syndrome X), myositis, nephritis, obesity, osteopenia, osteoporosis, Parkinson' s disease, periodontal disease, polyarteritis, polychondritis, psoriasis, scleroderma, sinusitis, Sjogren's syndrome, spastic colon, systemic candidi
- a compound herein reduces inflammation or pain which comprise contacting a system with a compound described herein in an amount effective for modulating (e.g., inhibiting) the activity of a pain signal or inflammation signal.
- methods for identifying a compound that reduces inflammation or pain which comprise: contacting a system with a compound of Formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV or XVI; and detecting a pain signal or inflammation signal, whereby a compound that modulates the pain signal relative to a control molecule is identified as a compound that reduces inflammation of pain.
- pain signals are formalin-stimulated pain behaviors and examples of inflammation signals include without limitation a level of a pro-inflammatory molecule.
- the invention also in part pertains to methods for modulating angiogenesis in a subject, and methods for treating a condition associated with aberrant angiogenesis in a subject.
- methods for determining whether a compound herein modulates angiogenesis which comprise contacting a system with a compound described herein in an amount effective for modulating (e.g., inhibiting) angiogenesis or a signal associated with angiogenesis.
- Signals associated with angiogenesis are levels of a pro-angiogenesis growth factor such as VEGF.
- Methods for assessing modulation of angiogenesis also are known, such as analyzing human endothelial tube formation (BD BioCoatTM Angiogenesis System from BD Biosciences).
- identifying a compound that modulates angiogenesis which comprise contacting a system with a compound of Formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV or XVI; and detecting angiogenesis in the system or an angiogenesis signal, whereby a compound that modulates the angiogenesis or angiogenesis signal relative to a control molecule is identified as a compound that modulates angiogenesis.
- methods for treating an angiogenesis condition which comprise administering a compound described herein to a subject in need thereof in an amount effective to treat the angiogenesis condition.
- Angiogenesis conditions include without limitation solid tumor cancers, varicose disease and the like.
- Any suitable formulation of a compound described above can be prepared for administration.
- Any suitable route of administration may be used, including, but not limited to, oral, parenteral, intravenous, intramuscular, transdermal, topical and subcutaneous routes.
- the mode of administration, and the type of treatment desired e.g., prevention, prophylaxis, therapy; the compounds are formulated in ways consonant with these parameters.
- Preparation of suitable formulations for each route of administration are known in the art. A summary of such formulation methods and techniques is found in Remington's Pharmaceutical Sciences, latest edition, Mack Publishing Co., Easton, PA, which is incorporated herein by reference.
- each substance or of the combination of two substances will generally include a diluent as well as, in some cases, adjuvants, buffers, preservatives and the like.
- the substances to be administered can be administered also in liposomal compositions or as microemulsions.
- formulations can be prepared in conventional forms as liquid solutions or suspensions or as solid forms suitable for solution or suspension in liquid prior to injection or as emulsions.
- Suitable excipients include, for example, water, saline, dextrose, glycerol and the like.
- Such compositions may also contain amounts of nontoxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like, such as, for example, sodium acetate, sorbitan monolaurate, and so forth.
- Systemic administration may also include relatively noninvasive methods such as the use of suppositories, transdermal patches, transmucosal delivery and intranasal administration.
- Oral administration is also suitable for compounds of the invention. Suitable forms include syrups, capsules, tablets, as is understood in the art.
- the appropriate dosage of the a compound described above often is 0.01-15 mg/kg, and sometimes 0.1-10 mg/kg. Dosage levels are dependent on the nature of the condition, drug efficacy, the condition of the patient, the judgment of the practitioner, and the frequency and mode of administration; however, optimization of such parameters is within the ordinary level of skill in the art.
- the invention provides methods to treat conditions such as cancer and inflammation by administering to a subject in need of such treatment a therapeutically effective amount of a therapeutic agent that binds to certain DNA segments and administering to the same subject a PARP or CK2 modulator in an amount that is effective to enhance the activity of the therapeutic agent.
- a PARP or CK2 modulator is an agent that inhibits or enhances a biological activity of a PARP protein or a CK2 protein, and is generically referred to hereafter as a "modulator.”
- the therapeutic agent and the modulator may be administered together, either as separate pharmaceutical compositions or admixed in a single pharmaceutical composition.
- the therapeutic agent and the modulator may also be administered separately, including at different times and with different frequencies, as long as the modulator is administered at a time that increases the potency of the therapeutic agent.
- the modulator may be administered by any known route, such as orally, intravenously, intramuscularly, nasally, and the like; and the therapeutic agent may also be administered by any conventional route. In many embodiments, at least one and optionally both of the modulator and the therapeutic agent may be administered orally.
- the modulator and the therapeutic agent are administered at the same time, whether in separate dosages or admixed in a single dosage.
- the modulator and therapeutic agent are preferably combined into a single pharmaceutical composition, so the treated patient may receive a single oral dosage or a single injection, for example.
- the amount of each of these materials to be administered will vary with the route of administration, the condition of the subject, other treatments being administered to the subject, and other parameters.
- the therapeutic agents of the invention may, of course, cause multiple desired effects; and the amount of modulator to be used in combination with the therapeutic agent should be an amount that increases one or more of these desired effects.
- the modulator is to be administered in an amount that is effective to enhance a desired effect of the therapeutic agent.
- An amount is "effective to enhance a desired effect of the therapeutic agent", as used herein, if it increases by at least about 25% at least one of the desired effects of the therapeutic agent alone.
- it is an amount that increases a desired effect of the therapeutic agent by at least 50% or by at least 100% (i.e., it doubles the effective activity of the therapeutic agent.) In some embodiments, it is an amount that increases a desired effect of the therapeutic agent by at least 200%.
- the amount of a modulator that increases a desired effect of a therapeutic agent may be determined using in vitro methods, such as cell proliferation assays.
- the therapeutic agents of the invention are useful to counter hyperproliferative disorders such as cancer, thus they reduce cell proliferation.
- a suitable amount of a modulator could be the amount needed to enhance an antiproliferative effect of a therapeutic agent by at least 25% as determined in a cell proliferation assay.
- the modulator used in the present invention enhances at least one desired effect produced by the therapeutic agent it is used with, thus the combinations of the inveniton provide a synergistic effect, not merely an additive effect.
- the modulators themselves are at times useful for treating the same types of conditons, and thus may also have some direct effect in such assays.
- the "amount effective to increase a desired effect” must be a synergistic enhancement of the activity of the therapeutic agent that is attributable to enhancement by the modulator of an effect of the therapeutic agent, rather than a simple additive effect that would be expected with separate administration of the two materials.
- the modulator can be used in an amount (concentration) that would not be expected to have any apparent effect on the treated subject or the in vitro assay, so the increased effect achieved with the combination is directly attributable to a synergistic effect.
- the present invention includes methods and compositions for treating a patient having a cell proliferation disorder or an inflammatory disorder with a therapeutic agent as described herein, and a "modulator" described above, where the timing of administration of the modulator permits it to enhance a desired effect of the therapeutic agent .
- Modulators of PARP and CK2 are known. Inhibitors of PARP are well known in the art, and some have been shown to potentiate the activity of other drugs for certain uses. For example, it has been reported that treating a carcinoma cell colony with a PARP inhibitor at a concentration that had no substantial growth inhibition or cellular toxicity alone increased the activity of cytotoxic agents temozolomide and topotecan substantially. C. R. Calabrese, et al., Clin. Cancer Res., vol. 9, 2711-18 (July 2003). This effect is believed to be related to the role PARP plays in DNA repair: because PARP promotes repair of damaged DNA, it is thought to increase the effects of compounds that act by damaging DNA. These include compounds that alkylate DNA, which may include temozolomide, and topoisomerase inhibitors such as topotecan. Id.
- the present invention relates to the use of a "modulator" as described above in combination with a therapeutic agent that can act by binding to regions of DNA that can form certain quadruplex structures; the therapeutic agents have anticancer activity on their own, but their activity is enhanced when they are used in combination with a modulator.
- This synergistic effect allows the therapeutic agent to be administered in a lower dosage while achieving equivalent or higher levels of at least one desired effect.
- the therapeutic agents of the invention are compounds that bind to certain motifs in nucleic acids.
- the therapeutic agent to be used can be selected from several different classes of compounds, such as those that bind to quadruplex-forming regions of DNA.
- the therapeutic agents are useful for the treatment of cancer and other indications such as inflammatory disorders, and methods for making and using them are known in the art. Several preferred classes of these therapeutic agents are described below. Each class of therapeutic agents can be used in combination with any active PARP inhibitor, including but not limited to those disclosed herein.
- the therapeutic agent can be a compound of formula (TA1-1):
- V is H, halo, or NR 1 R 2 ;
- A is H, fluoro, or NR 1 2 ;
- Z is O, S, NR 1 or CH 2 ;
- U is OR 2 or NR 1 R 2 ;
- X is OR 2 , NR 1 R 2 , halo, azido, or SR 2 ; n is 1-3; wherein in NR 1 R 2 , R 1 and R 2 may form a double bond or a ring, each of which is optionally substituted;
- R 1 is H or a C 1-6 alkyl
- R 2 is H or a C 1-10 alkyl or C 2-10 alkenyl optionally containing one or more non-adjacent heteroatoms selected from N, O, and S, and optionally substituted with a carbocyclic or heterocyclic ring; or R 2 is an optionally substituted heterocyclic ring, aryl or heteroaryl;
- W is an optionally substituted aryl or heteroaryl, which may be monocyclic or fused with a single or multiple ring and optionally containing a heteroatom; or a compound having formula (TA1-2): wherein V, A, X, Z and U are as defined in formula TA1-1, and W is selected from the group consisting of
- the therapeutic agent is a compound having formula (TA1-1A):
- the therapeutic agent of the combinations of the invention is a compound of this formula: and pharmaceutically acceptable salts, esters and prodrugs thereof; wherein V is H, halo, or NR 1 R 2 ;
- A is H, fluoro, or NR 1 2 ;
- Z is O, S, NR 1 or CH 2 ;
- U is OR 2 or NR 1 R 2 ;
- X is OR 2 , NR 1 R 2 , halo, azido, or SR 2 ; n is 1-3; wherein in NR 1 R 2 , R 1 and R 2 may form a double bond or a ring, each of which is optionally substituted;
- R 1 is H or a C 1-6 alkyl
- R is H or a C 1-10 alkyl or C 2-10 alkenyl optionally containing one or more non-adjacent heteroatoms selected from N, O, and S, and optionally substituted with a carbocyclic or heterocyclic ring; or R 2 is an optionally substituted heterocyclic ring, aryl or heteroaryl;
- W is an optionally substituted aryl or heteroaryl, which may be monocyclic or fused with a single or multiple ring and optionally containing a heteroatom; or a compound having formula (TA3-2) wherein V, A, X, Z and U are as defined in formula 1, and W is selected from the group consisting of
- the therapeutic agent of the combinations of the invention is a compound of this formula:
- B, X, A, or V is absent if Z 2 , Z 3 , or Z 4 , respectively, is N , and independently H, halo, azido, R 2 , CH 2 R 2 , SR 2 , OR 2 or NR 1 R 2 if Z 2 , Z 3 , or Z 4 , respectively, is C; or
- a and V, A and X, or X and B may form a carbocyclic ring, heterocyclic ring, aryl or heteroaryl, each of which may be optionally substituted and/or fused with a cyclic ring;
- Z 1 , Z 2 , Z 3 and Z 4 are C or N, provided any two N are non-adjacent;
- W together with N and Z forms an optionally substituted 5- or 6-membered ring that is fused to an optionally substituted saturated or unsaturated ring;
- said saturated or unsaturated ring may contain a heteroatom and is monocyclic or fused with a single or multiple carbocyclic or heterocyclic rings;
- R 4 is H, a C 1-10 alkyl or C 2-10 alkenyl optionally containing one or more non-adjacent heteroatoms selected from N, O and S, and optionally substituted with a carbocyclic or heterocyclic ring; or R 3 and R 4 together with N may form an optionally substituted ring; each R 5 is a substituent at any position on ring W; and is H, OR 2 , amino, alkoxy, amido, halogen, cyano or an inorganic substituent; or R 5 is C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, -CONHR 1 , each optionally substituted by halo, carbonyl or one or more non-adjacent heteroatoms; or two adjacent R 5 are linked to obtain a 5-6 membered optionally substituted carbocyclic or heterocyclic ring that may be fused to an additional optionally substituted carbocyclic or heterocyclic ring; and n is 1-6.
- B may be absent when Z 1 is N, or is H or a halogen when Z 1 is C.
- W together with N and Z form a group having the formula selected from the group consisting of
- R 6 is H, or a substituent known in the art, including but not limited to hydroxyl, alkyl, alkoxy, halo, amino, or amido; and ring S and ring T may be saturated or unsaturated.
- W together with N and Z forms a 5- or 6-membered ring that is fused to a phenyl. In other embodiments, W together with N and Z forms a 5- or 6- membered ring that is optionally fused to another ring, when U is NR 1 R 2 , provided U is not NH 2 . In certain embodiments, W together with N and Z forms a 5- or 6-membered ring that is not fused to another ring, when U is NR 1 R 2 (e.g., NH 2 ).
- the compounds of the present invention have the general formula (TA4-2A) or (TA4-2B):
- A, B, V, X, U, Z, Z 1 , Z 2 , Z 3 , Z 4 and n are as described for TA4-1 ;
- R 6 is H, Ci_ 6 alkyl, hydroxyl, alkoxy, halo, amino or amido;
- Z and Z 5 may optionally form a double bond.
- U may be NR 1 R 2 , wherein R 1 is H, and R 2 is a C 1-10 alkyl optionally substituted with a heteroatom, a C 3 . 6 cyclo alkyl, aryl or a 5-14 membered heterocyclic ring containing one or more N, O or S.
- R 2 may be a C 1-10 alkyl substituted with an optionally substituted morpholine, thiomorpholine, imidazole, aminodithiadazole, pyrrolidine, piperazine, pyridine or piperidine.
- R 1 and R 2 together with N form an optionally substituted piperidine, pyrrolidine, piperazine, morpholine, thiomorpholine, imidazole, or aminodithiazole.
- the therapeutic agent to be combined with a PARP inhibitor can be selected from compounds having this formula:
- V, X, and Y are absent if attached to a heteroatom other than Nitrogen, and independently H, halo, azido, R 2 , CH 2 R 2 , SR 2 , OR 2 or NR 1 R 2 when attached to C or N; or wherein V and X, or X and Y may form a carbocyclic ring, heterocyclic ring, aryl or heteroaryl, each of which may be optionally substituted and/or fused with a cyclic ring;
- Z 1 , Z 2 and Z 3 are C, N, O or S;
- W together with N and Z forms an optionally substituted 5- or 6-membered ring that is fused to an optionally substituted aryl or heteroaryl, wherein said aryl or heteroaryl may be monocyclic or fused with a single or multiple ring, and wherein said ring optionally contains a heteroatom;
- R 1 and R 3 are independently H or C 1-6 alkyl; each R 2 is H, or a C 1-10 alkyl or C 2-10 alkenyl each optionally substituted with a halogen, one or more non-adjacent heteroatoms selected from N, O and S, a carbocyclic ring, a heterocyclic ring, an aryl or heteroaryl, wherein each ring is optionally substituted; or R 2 is an optionally substituted carbocyclic ring, heterocyclic ring, aryl or heteroaryl; or R 2 is COR 1 or S(O) x R 1 wherein x is 1-2;
- R 4 is H, a C 1-10 alkyl or C 2-10 alkenyl optionally containing one or more non-adjacent heteroatoms selected from N, O and S, and optionally substituted with a carbocyclic or heterocyclic ring; or R 3 and R 4 together with N may form an optionally substituted ring; each R 5 is a substituent at any position on W; and is H, OR 2 , amino, alkoxy, amido, halogen, cyano or an inorganic substituent; or R 5 is C 1-6 alkyl, C 2-6 alkenyl, -CONHR 1 , each optionally substituted by halo, carbonyl or one or more non-adjacent heteroatoms; or two adjacent R 5 are linked to obtain a 5-6 membered optionally substituted carbocyclic or heterocyclic ring, optionally fused to an additional optionally substituted carbocyclic or heterocyclic ring; and n is 1-6.
- ring T may form an optionally substituted 5- membered ring selected from the group consisting of:
- W together with N and Z may form an optionally substituted 5- or 6-membered aryl or heteroaryl ring that is fused to an optionally substituted aryl or heteroaryl selected from the group consisting of:
- W together with N and Z may form a group having the formula selected from the group consisting of
- R 6 is H, or a substituent known in the art, including but not limited to hydroxyl, alkyl, alkoxy, halo, amino, or amido;
- Ring S and M may be saturated or unsaturated.
- W together with N and Z may form a 5- or 6-membered ring that is fused to a phenyl.
- the compounds of the present invention have the general formula (TA5-2A) or (TA5-2B):
- Z and Z 4 may optionally form a double bond.
- U may be SO 2 NR 1 R 2 , wherein R 1 is H, and R 2 is a C 1-10 alkyl optionally substituted with a heteroatom, a C 3 _ 6 cycloalkyl, aryl or a 5-14 membered heterocyclic ring containing one or more N, O or S.
- R 2 may be a C 1-10 alkyl substituted with an optionally substituted morpholine, thiomorpholine, imidazole, aminodithiadazole, pyrrolidine, piperazine, pyridine or piperidine.
- R 1 and R 2 together with N form an optionally substituted piperidine, pyrrolidine, piperazine, morpholine, thiomorpholine, imidazole, or aminodithiazole.
- U is SO 2 NR 1 -(CR 1 2 ) n -NR 3 R 4 ; n is 1-4; each R 1 is H or alkyl; and R 3 and R 4 in NR 3 R 4 together form an optionally substituted piperidine, pyrrolidine, piperazine, morpholine, thiomorpholine, imidazole, or aminodithiazole.
- U is SO 2 NH-(CH 2 ) n -NR 3 R 4 wherein R 3 and R 4 together with N form an optionally substituted pyrrolidine, which may be linked to (CH 2 ) n at any position in the pyrrolidine ring. In one embodiment, R 3 and R 4 together with N form an N-methyl substituted pyrrolidine.
- the present invention provides compounds having formula (TA5-1), (TA5-2A) or (TA5-2B), wherein: each of V and Y if present is independently H or halogen (e.g., chloro or fluoro);
- X is -(R 5 )R 1 R 2 , wherein R 5 is C or N and wherein in each -(R 5 )R 1 R 2 , R 1 and R 2 together may form an optionally substituted aryl or heteroaryl ring;
- Z is NH or N-alkyl (e.g., N-CH 3 );
- W together with N and Z forms an optionally substituted 5- or 6-membered ring that is fused with an optionally substituted aryl or heteroaryl ring; and
- U is -SO 2 R 5 R 6 -(CH 2 ) n -CHR 2 -NR 3 R 4 , wherein R 5 is CR 1 or N; R 1 is H or alkyl; R 6 is H or C 1-10 alkyl and wherein in the -CHR 2 -NR 3 R 4 moiety each R 3 or R 4 together with the C may form an optionally substituted heterocyclic or heteroaryl ring, or wherein in the -CHR 2 -NR 3 R 4 moiety each R 3 or R 4 together with the N may form an optionally substituted carbocyclic, heterocyclic, aryl or heteroaryl ring.
- the present invention provides compounds having formula (TA5-1), (TA5-2A) or (TA5-2B), wherein:
- V and Y if present is H or halogen (e.g., chloro or fluoro);
- X if present is -(R 5 )R 1 R 2 , wherein R 5 is C or N and wherein in each -(R 5 )R 1 R 2 , R 1 and R 2 together may form an optionally substituted aryl or heteroaryl ring;
- Z is NH or N-alkyl (e.g., N-CH 3 );
- U is -SO 2 R 5 R 6 -(CH 2 ) n -CHR 2 -NR 3 R 4 ,
- R 5 is CR 1 or N
- R 6 is H or alkyl and wherein in the -CHR 2 -NR 3 R 4 moiety each R 3 or R 4 together with the C may form an optionally substituted heterocyclic or heteroaryl ring, or wherein in the - CHR 2 -NR 3 R 4 moiety each R 3 or R 4 together with the N may form an optionally substituted carbocyclic, heterocyclic, aryl or heteroaryl ring.
- the compounds of the present invention have the general formula (TA5-3):
- the compounds of the present invention have the general formula (TA5-4A) or (TA5-4B):
- the therapeutic agent for the combinations of the invention can be a compound of the formula:
- X is H, OR 2 , NR 1 R 2 , halogen, azido, SR 2 or CH 2 R;
- A is H, halogen, NR 1 R 2 , SR 2 , OR 2 , CH 2 R 2 , azido or NR 1 - (CR 1 2 ) n - NR 3 R 4 ;
- Z is O, S, NR 1 or CH 2 ;
- U is R 2 , OR 2 , NR 1 R 2 or NR 1 - (CR 1 2 ) n - NR 3 R 4 provided U is not H;
- W is an optionally substituted aryl or heteroaryl, which may be monocyclic or fused with a single or multiple ring optionally containing a heteroatom; wherein R 1 and R 2 together with N in NR 1 R 2 , and R 3 and R 4 together with N in NR 3 R 4 may independently form an optionally substituted 5-6 membered ring containing N, and optionally O or S;
- R 1 and R 3 are independently H or a C 1-6 alkyl
- R 2 and R 4 are independently H, or a C 1-10 alkyl or C 2-10 alkenyl optionally containing one or more non-adjacent heteroatoms selected from N, O, and S, and optionally substituted with a substituted or unsubstituted aryl, heteroaryl, carbocyclic, or heterocyclic ring; or R 2 is an optionally cycloalkyl, substituted heterocyclic ring, aryl or heteroaryl;
- A is H, halogen, azido, SR 2 , OR 2 , CH 2 R 2 , NR 1 R 2 , or NR 1 - (CR 1 2 ) n - NR 3 R 4 ;
- Z, U, W, R 1 , R 2 , R 3 and R 4 are as defined in formula TA6-1; and
- each W in the above formula TA6-1 or TA6-1A may be an optionally substituted phenyl, pyridine, biphenyl, naphthalene, phenanthrene, quinoline, isoquinoline, quinazoline, cinnoline, phthalazine, quinoxaline, indole, benzimidazole, benzoxazole, benzthiazole, benzofuran, anthrone, xanthone, acridone, fluorenone, carbazolyl, pyrimido[4,3-b]furan, pyrido[4,3-b]indole, pyrido[2,3-b]indole, dibenzofuran, acridine or acridizine.
- W is an optionally substituted phenyl.
- the present invention utilizes the above therapeutic agents in combination with at least one modulator.
- Examples of PARP inhibitors are known in the art, and are disclosed, for example, in CR. Calebrese, et al., Clin. Cancer Res. vol. 9, 2711-18 (2003); SJ. Veuger, et al., Cancer Res. vol. 63, 6008-15 (2003); CR. Calabrese et al., J. Natl. Cancer Inst. 96(1), 56-67 (2004); "Potent Novel PARP Inhibitors," Expert Reviews in Molecular Medicine, vol. 7(4) (March 2005); and P. Jagtap, Nature Rev.: Drug Discovery, vol. 4, 421-40 (20045).
- PARP inhibitors disclosed in these documents are suitable for use in the methods and compositions of the present invention.
- Additional PARP inhibitors that can be used include, for example, 10-(4-methyl-piperazin-l-ylmethyl)-2H-7-oxa-l,2-diaza-benzo[de]anthracen-3- one (GPI 15427) and 2-(4-methyl-piperazin-l-yl)-5H-benzo[c][l,5]naphthyridin-6-one (GPI 16539).
- GPI 15427 10-(4-methyl-piperazin-l-ylmethyl)-2H-7-oxa-l,2-diaza-benzo[de]anthracen-3- one
- GPI 16539 2-(4-methyl-piperazin-l-yl)-5H-benzo[c][l,5]naphthyridin-6-one
- Representative, but non-limiting, examples of PARP inhibitors that are suitable for use in the invention
- Modulators that can be utilized in combination with a therapeutic agent described above also include compounds having structures of Formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI or XII described herein.
- the compound TA1-1A is a preferred therapeutic agent for use in the methods and compositions of the invention. More detail on suitable methods for its formulation and administration are provided in U.S. Provisional Application Serial No. 60/803,864 to Lim, et al., which was filed on June 3, 2006.
- the invention also in part provides pharmaceutical compositions comprising at least one therapeutic agent within the scope of the invention as described herein in combination with at least one modulator.
- the composition may comprise a diluent or other pharmaceutically acceptable excipients.
- the appropriate dosage of the therapeutic agent is typically 0.01-15 mg/kg, preferably 0.1-10 mg/kg. Dosage levels are dependent on the nature of the condition, drug efficacy, the condition of the patient, the judgment of the practitioner, and the frequency and mode of administration; however, optimization of such parameters is within the ordinary level of skill in the art.
- the dosage of a modulator is typically between about 0.01- 15 mg/kg, and about 0.1-10 mg/kg.
- a modulator may be separately active for treating a cancer.
- the dosage of a modulator will frequently be two-fold to ten-fold lower than the dosage required when the modulator is used alone to treat the same condition or subject. Determination of a suitable amount of the modulator for use in combination with a therapeutic agent is readily determined by methods known in the art.
- Also provided are methods for modulating the activity of a PARP protein which comprises contacting a system comprising the PARP protein with a composition described herein in an amount effective for modulating (e.g., inhibiting) the activity of the protein.
- the system in such embodiments can be a cell-free system or a system comprising cells.
- methods for reducing cell proliferation, and optionally inducing apoptosis which comprises contacting cells with a composition or a combination therapy as described herein, wherein a therapeutic agent is administered in an amount effective to reduce proliferation of the cells, and a PARP inhibitor is administered in an amount sufficient to enhance the efficacy of the therapeutic agent.
- the cells in such embodiments can be in a cell line, in a tissue or in a subject (e.g., a research animal or human).
- the invention also in part provides methods for treating a condition related to aberrant cell proliferation.
- methods of treating a cell proliferative condition in a subject which comprises administering a therapeutic agent described herein and a PARP inhibitor described herein to a subject in need of treatment for a cell proliferative disorder; the therapeutic agent and the PARP inhibitor are administered in amounts effective to treat the cell proliferative condition.
- the subject may be a research animal (e.g., rodent, dog, cat, monkey), optionally containing a tumor such as a xenograft tumor (e.g., human tumor), for example, or may be a human.
- a cell proliferative condition sometimes is a tumor or non-tumor cancer, including but not limited to, cancers of the colorectum, breast, lung, liver, pancreas, lymph node, colon, prostate, brain, head and neck, skin, liver, kidney, blood and heart (e.g., leukemia, lymphoma, carcinoma).
- Any suitable formulation of the therapeutic agent and the PARP inhibitor can be prepared for administration, either together or separately. Any suitable route of administration may be used for each component, including but not limited to oral, parenteral, intravenous, intramuscular, transdermal, topical and subcutaneous routes.
- the two substances used together may be administered separately or together. When administered together, they may be in separate dosage forms, or they may be combined into a single combination drug.
- pharmaceutical compositions comprising a therapeutic agent as described herein and at least one PARP inhibitor, and a pharmaceutically acceptable excipient.
- Ethyl 3-bromo-4-pyridine carboxylate 1.15 g, 5.0 mmol
- 2-amino-4- methoxycarbonyl-phenylboronic acid (1.04 g, 4.5 mmol)
- sodium acetate (1.64 g, 20 mmol)
- l,l '-bis(diphenylphosphino)fer ⁇ ocene palladium (II) chloride (complexed with dichloromethane) (182 mg, 0.25 mmol) and dimethylfo ⁇ namide (7.5 mL) were combined in a flask.
- the flask was evacuated and filled with nitrogen twice and heated to 125°C with stirring for 12 hours or until LCMS indicated the absence of any starting material.
- the material was purified by flash chromatography (SiO 2 , 1: 1 to 9: 1 gradient of EtOAc/Hexanes) to obtain the ester.
- the material was dissolved in methanol and 6N aqueous NaOH and the mixture stirred at 50°C for 30 minutes. The volatiles were removed in vacuo. The residue was triturated from acetic acid/THF/methanol using a mixture of hexanes and ethylacetate. Filtration and drying provided 147 mg of 5-(3- chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid.
- methyl 5-chloropyrimido[4,5-c]quinoline-8-carboxylate (10 mg) was mixed with 3,5-difluoroaniline (100 mg) in NMP (0.1 ml). The mixture was heated under microwaves at 120°C for 10 minutes. Water was added and the material extracted with CH 2 Cl 2 . The solvent was removed. Trituration in a mixture of ethylacetate and hexanes and filtration provided methyl 5 -(3, 5- difluorophenylamino)pyrimido[4,5-c]quinoline-8-carboxylate. This material was suspended in a 1 : 1 mixture of THF and MeOH (2ml) and a 5 N aqueous solution of Lithium Hydroxide was added.
- methyl-5-bromo-2-(methylthio)pyrimidine-4-carboxylate was prepared according to the procedure used in process 2 for the preparation of methyl-5- bromopyrimidine-4-carboxylate.
- methyl 5-chloro-3-(methylthio)pyrimido[4,5-c]quinoline-8-carboxylate (1.0 eq, 182 mg, 0.57 mmol) was mixed with aniline (0.5 ml) in NMP (1mI). The mixture was heated under microwave for 10 minutes at 120°C. Water was added and the resulting solid was filtered and dried. The compound was triturated in EtOAc and hexanes and filtered to afford methyl 3-(methylthio)-5-(phenylamino)pyrimido[4,5- c]quinoline-8-carboxylate as a yellow solid.
- This material was suspended in CH 2 CI 2 (4 ml) and meta-chloroperbenzoic acid (77% pure, 2.5 eq, 165 mg, 0.737 mmol) was added in small portions. After one hour, an additional amount (100 mg) of mcpba was added and the mixture stirred for 1.5 hours. After addition of more CH 2 Cl 2 , the organic phase was washed with water (4x), dried over Na 2 SO 4 and the solution was filtered through a pad of silica gel, eluting with a MeOH/CH 2 Cl 2 mixture.
- Nl,Nl-dimethyl-N2-(thieno[3,2-c]quinolin-4-yl)ethane-l,2-diamine was prepared according to the procedure in process 24 using N, N-dimethyl ethylene diamine. Preparative HPLC and genevac evaporation afforded the expected material as a TFA salt. LCMS (ES): 95% pure, m/z 272 [M+1] + .
- Methyl 2-acetamido-4-oxo-4,5-dihydrothiazolo[4,5-c]quinoline-7- carboxylate was prepared according to the procedure used in process 2, starting from methyl 2-acetamido-5-bromothiazole-4-carboxylate. Methyl 2-acetamido-4-oxo-4,5- dihydrothiazolo[4,5-c]quinoline-7-carboxylate was isolated as a black solid (106 mg, 37% yield). LCMS (ES): 95% pure, m/z 318 [M+1] + .
- methyl 4-chlorothiazolo[4,5-c]quinoline-7- carboxylate (1.0 eq, 23 mg, 0.084 mmol) and aniline (13 eq, 0.1 ml, 1.1 mmol) were mixed in NMP (0.1 ml). The mixture was heated in a microwave oven at 120°C for 10 min. The intermediate ester was purified by preparative HPLC and isolated as a solid after genevac evaporation. The solid was stirred in a (1: 1 : 1, v:v:v) mixture of THF, MeOH and water (0.6 ml) with LiOH (41 mg) at room temperature for 2 hours.
- Modulatory activity of compounds described herein was assessed in vitro in cell-free CK2 assays. Modulatory activity of compounds described herein also are assessed in vitro in cell-free PARP assays. These assays are described hereafter.
- Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate).
- ADB Assay Dilution Buffer
- RRRDDDSDDD substrate peptide
- PARP assays are conducted using a chemiluminescent PARP assay kit (Trevigen). Briefly, reactions are performed in Histone-coated strip wells, by adding 10 microliters test compound dissolved in IX PARP Buffer (prepared by mixing 20X PARP buffer diluted with high-purity water) and 15 microliters diluted PARP-HSA enzyme (diluted in IX PARP buffer, 0.1 unit per well) to 25 microliters PARP cocktail (prepared from 10X PARP cocktail and 10X activated DNA, both 2.5 microliters per well and 20 microliters per well of IX PARP buffer). The reactions are incubated at ambient temperature for 60 minutes, then the liquid was removed.
- IX PARP Buffer prepared by mixing 20X PARP buffer diluted with high-purity water
- diluted PARP-HSA enzyme diluted in IX PARP buffer, 0.1 unit per well
- PARP cocktail prepared from 10X PARP cocktail and 10X activated DNA, both 2.5 microliters per well and 20 microliters per well of IX PAR
- STREP-HRP Haseradish Peroxidase
- IX Strep-Diluent 50 microliters of STREP-HRP (Horseradish Peroxidase) solution (diluted 500-fold in IX Strep-Diluent) was added and the reactions were allowed to incubate for 30 minutes at ambient temperature. The liquid was removed and, after washing the wells four times with PBS (200 ul), 50 microliters each of PeroxyGlo A and B (Chemiluminescent Horseradish Peroxidase substrates) are added and the resulting chemiluminescence quantified on the SpectraMax M5 plate reader.
- PeroxyGlo A and B Chemiluminescent Horseradish Peroxidase substrates
- Tables 10 to 15 show modulatory effects of compounds on CK2 activity.
- Table 12 shows modulatory effects of compounds on PARP and CK2.
- a representative cell-proliferation assay protocol using Alamar Blue dye (stored at 4°C, use 20ul per well) is described hereafter.
- 96-well plate setup and compound treatment a. Split and trypsinize cells.
- cells are cultured with a test compound for approximately four days, the dye then is added to the cells and fluorescence of non-reduced dye is detected after approximately four hours.
- Different types of cells can be utilized in the assays (e.g., HCT-116 human colorectal carcinoma cells, PC-3 human prostatic cancer cells and MiaPaca human pancreatic carcinoma cells). Anti-proliferative effects of representative compounds are provided hereafter.
- the human leukemia Jurkat T-cell line was maintained in RPMI 1640 (Cambrex) supplemented with 10% fetal calf serum and 50 ng/ml Geutamycin. Before treatment cells were washed, resuspended at a density of about 10 6 cells/milliliter in medium containing 1% fetal calf serum and incubated in the presence of indicated mounts of drug for two hours.
- each of the two compounds significantly inhibited endogenous CK2 activity as compared to the untreated control.
- Each of the two compounds also more potently inhibited endogenous CK2 activity as compared to reference compound 4,5,6,7-tetrabromobenzotriazole (TBB), a known CK2 inhibitor (Ruzzene et al, Biochem J. 15: 364(Pt l):41-7 (2002)).
- Bioanalysis was performed using a Quattro Micro LC/MS/MS instrument in the MRM detection mode, with an internal standard (IS). Briefly, 15 DL plasma samples were prepared for analysis using protein precipitation with 120 ⁇ L of acetonitrile. The supernatants were transferred into a 96 well plate and subjected to LC-MS/MS analysis using a Phenomenex Polar-RP HPLC column. The mobile phases were 10 mM NH 4 HCO 3 in water (Solution-A) and 10 mM NH 4 HCO 3 in methanol (Solution-B). The column was initially equilibrated with 25 % Solution-B and followed with 100% Solution B over 5 minutes. The method had a dynamic range from 1 to 10,000 ng/mL. Quantitation of the analytes was performed in the batch mode with two bracketing calibration curves according to the bioanalytical sample list.
- Table 21 Estimated pharmacokinetic parameters after intravenous and oral dosing at 5 and 25 mg/kg, respectively.
- Example 8 Evaluation of Compound Efficacy in Tumor Suppression [0216] The in vivo activity of compound Al and compound A2 (shown previously) was assessed by intravenous and oral administration to tumor-bearing xenograft mice. The in vivo experiments followed protocols approved by the Animal Use and Care Committee. Female NCr nu/nu mice were purchased from Taconic Farms and group housed in a ventilated rack system on a 12/12 light cycle. All housing materials and water were autoclaved prior to use. The mice were fed ad libitum with gamma irradiated laboratory chow and acidified water. Animals were handled under laminar- flow hoods.
- Compound A1 also was administered orally to MiaPaca xenograft animals and inhibited tumor growth.
- Compound A1 was formulated as a sodium salt at 10 mg/mL with 2% PEG 300 and buffered to pH 8.4 using sodium phosphate buffer.
- Compound A1 when administered orally to the animals at a dose of 100 mg/kg QDx8 and then 200 mg/kg QDx5 significantly inhibited tumor growth relative to an untreated control group.
- GemzarTM administered at a dose of 80 mg/kg IP Q3D was used as a positive control.
- Compound A1 also was delivered by oral administration at 100 mg/kg to animals bearing MCF-7 xenografts and at 150 mg/kg to animals bearing PC-3 xenografts, and in both sets of studies, significantly inhibited tumor growth. [0220] It also was determined that compound A1 reduced CK2 activity in tumors. Assessment of CK2 activity in tumors revealed that tumors from animals treated with compound A1 had about 40% of the CK2 activity of tumors from animals not treated with compound A1 or treated with GemzarTM.
- caspase staining also was assessed as a biomarker for compound A1 treatment of tumors. In animals treated with 60 mg/kg of compound A1 by IV administration, caspase-3 cell staining levels were four-fold greater than in untreated control cells. These results suggest caspase-3 staining can be a useful biomarker for monitoring inhibition of cell proliferation and tumor inhibition.
- Grp 5 Mean 96.51 100mg/kg CX-501 1 IP BID xl7days
- Tumor pharmacokinetic studies of compound A2 were carried out in which 30 mg/kg of the compound was dosed IV QDx6. Plasma, blood and tumor samples were taken on day 1, 4 and 6 and three animals sacrificed for each time point. Steady state was reached after about three days, the terminal slope decreases, the half life about doubles, the minimum concentration was 4-5 times higher after six days and there were no significant differences between day 4 and 6.
- Compounds described herein are profiled for in vitro modulatory activity against protein kinases other than CK2.
- the in vitro analysis is conducted using known protocols (e.g., assay protocols described at world-wide web address upstate.com/img/pdf/KP_Assay Protocol_Booklet_v3.pdf).
- Compounds described herein are screened in the assays and prioritized based upon modulatory activity against protein kinases other than CK2 and specificity for CK2 or PARP.
- a human endothelial tube formation assay was performed using the 96- well BD BioCoatTM Angiogenesis System from BD Biosciences, using the manufacturer' s recommended protocol. [0228] Briefly, HUVEC cells (from ATCC) were suspended in 150 ul of media containing 10% FBS at 4x10 cells/ml in each of the 96-wells of the matrigel coated plate in the presence or absence of various concentrations of compound A2. The plate was incubated for 18hrs at 37°C. The cells were stained with calcein AM and the results visualized by fluorescent microscopy or by phase contrast. It was observed that compound A2 inhibited tube formation in the assay described above over a concentration range of 1 to 5 ⁇ M.
- test compounds in aqueous solution are added at a volume of 5 ul, to a reaction mixture comprising 5 ul of 5x Reaction buffer (40mM MOPS, pH 7.0, ImM EDTA), 2.5 ul of recombinant human PIM-1 solution (10 ng), 2.5 ul of substrate peptide (KKRNRTLTK) and 10 ul of ATP solution - 98% (75 mM MgC12 37.5 uM ATP) 2% ([ ⁇ - 33P]ATP: 3000Ci/mmol - Perkin Elmer).
- 5x Reaction buffer 40mM MOPS, pH 7.0, ImM EDTA
- 2.5 ul of recombinant human PIM-1 solution (10 ng
- substrate peptide KKRNRTLTK
- 10 ul of ATP solution - 98% 75 mM MgC12 37.5 uM ATP
- kinase inhibition IC 50 data were determined using standardized radiometric kinase assays for each individual kinase, which entail filter binding of 33 P labeled substrate proteins by the kinase of interest. Each IC 50 value was determined over a range of 10 drug concentrations. Reaction conditions are available from the World Wide Web URL upstate.com/discovery/services/ic50_profiler.q.
- kinase inhibition data were determined using standardized radiometric kinase assays for each individual kinase, which entail filter binding of 33 P labeled substrate proteins by the kinase of interest. Each percentage of activity was determined at 0.5 ⁇ M concentration of the drug. Reaction conditions are available at the World Wide Web URL upstate.com/discovery/services/ic50_profiler.q.
- each Z 1 , Z 2 , Z 3 , and Z 4 is N or CR 3 ; each of Z 5 , Z 6 , Z 7 and Z 8 is N or CR 6 ; none, one or two of Z 1 -Z 4 are N and none, one or two of Z 5 -Z 8 are N; each R 3 and each R 6 is independently H or an optionally substituted C1-C8 alkyl, C2-C8 heteroalkyl, C2-C8 alkenyl, C2-C8 heteroalkenyl, C2-C8 alkynyl, C2-C8 heteroalkynyl, C1-C8 acyl, C2-C8 heteroacyl, C6-C10 aryl, C5-C12 heteroaryl, C7-C12 arylalkyl, or C6-C12 heteroarylalkyl group, or each R 3 and each R 6 is independently halo, OR, NR 2 , NR
- R 4 is H or an optionally substituted member selected from the group consisting of C1- C6 alkyl, C2-C6 heteroalkyl, and C1-C6 acyl; each R is independently H or an optionally substituted member selected from the group consisting of C 1-10 alkyl, C 2-10 alkenyl, C 2-10 heteroalkyl, C 3-8 carbocyclic ring, and C 3-8 heterocyclic ring optionally fused to an additional optionally substituted carbocyclic or heterocyclic; or R 5 is a C 1-10 alkyl, C 2-10 alkenyl, or C 2-10 heteroalkyl substituted with an optionally substituted C 3-8 carbocyclic ring or C 3-8 heterocyclic ring; and in each -NR 4 R 5 , R 4 and R 5 together with N may form an optionally substituted 3-8 membered ring, which may optionally contain an additional heteroatom selected from N, O and S as a ring member; provided that when -NR 4 R 5 in Formula (I)
- A4 The compound of any one of embodiments A1-A3, wherein the polar substituent is selected from a carboxy, a carboxy bioisostere or other acid-derived moiety that exists predominately as an anion at a pH of about 7 to 8.
- A5 The compound of any one of embodiments A1-A3, wherein the polar substituent contains an OH or NH, an ether oxygen, an amine nitrogen, an oxidized sulfur or nitrogen, a carbonyl, a nitrile, and a nitrogen-containing or oxygen-containing heterocyclic ring whether aromatic or non-aromatic.
- A6 The compound of any one of embodiments A1-A5, wherein the polar substituent is a carboxylate.
- A7 The compound of any one of embodiments A1-A5, wherein the polar substituent is a carboxylate or carboxylic acid.
- each R 7 is independently H or an optionally substituted member selected from the group consisting of C 1-10 alkyl, C 2-10 alkenyl, C 2-10 heteroalkyl, C 3-8 carbocyclic ring, and C 3-8 heterocyclic ring optionally fused to an additional optionally substituted carbocyclic or heterocyclic ring; or R 7 is a C 1-10 alkyl, C 2-10 alkenyl, or C 2-10 heteroalkyl substituted with an optionally substituted C 3-8 carbocyclic ring or C 3-8 heterocyclic ring.
- A9 The compound of any one of embodiments A1-A3, wherein the polar substituent is selected from the group consisting of carboxylic acid, carboxylic ester, carboxamide, tetrazole, triazole, carboxymethanesulfonamide, oxadiazole, oxothiadiazole, thiazole, aminothiazole and hydroxythiazole.
- the polar substituent is selected from the group consisting of carboxylic acid, carboxylic ester, carboxamide, tetrazole, triazole, carboxymethanesulfonamide, oxadiazole, oxothiadiazole, thiazole, aminothiazole and hydroxythiazole.
- A10 The compound of any one of embodiments A1-A9, wherein the polar substituent is at a position on the ring containing Z 1 -Z 4 .
- A11 The compound of embodiment any one of embodiments A1- A10, wherein the ring containing Z 1 -Z 4 includes one, two, three or four polar substituents.
- R 3P is a polar substituent and each R 3A , R 3B , R 3C and R 3D independently is selected from R 3 substituents.
- A14 The compound of any one of embodiments A1-A10, wherein at least one of Z 1 - Z 4 and Z 5 -Z 8 is a nitrogen atom.
- the compound of embodiment A14, the ring containing Z 1 -Z 4 or the ring containing Z 5 -Z 8 is independently an optionally substituted pyridine, pyrimidine or pyridazine ring.
- each R 6A , R 6B , R 6C and R 6D independently is selected from R 6 substituents defined in embodiment A1.
- A17 The compound of any one of embodiments A1-A17, wherein R 4 is H.
- A18 The compound of any one of embodiments A1-A17, wherein R 5 is an optionally substituted 3-8 membered ring.
- A19 The compound of any one of embodiments A1-A17, wherein R is a C 1-10 alkyl group substituted with an optionally substituted 3-8 membered ring.
- A24 The compound of any one of embodiments A1-A17, wherein R 5 is a C 1-3 alkyl substituted with an optionally substituted phenyl, pyridyl or morpholino ring substituent, or substituted with -NR 4 R 5 (e.g., -N(CH 3 ) 2 ).
- a composition that comprises a compound of embodiment A1 and a pharmaceutically acceptable carrier B1.
- each Z 1 , Z 2 , Z 3 , and Z 4 independently is N or CR 3 and none, one or two of Z 1 , Z 2 , Z 3 , and Z 4 is N; each R 3 , R 6A and R 6B independently is H or an optionally substituted C1-C8 alkyl, C2-C8 heteroalkyl, C2-C8 alkenyl, C2-C8 heteroalkenyl, C2-C8 alkynyl, C2-C8 heteroalkynyl, C1-C8 acyl, C2-C8 heteroacyl, C6-C10 aryl, C5-C12 heteroaryl, C7-C12 arylalkyl, or C6-C12 heteroarylalkyl group, or each R 3 , R 6A and R 6B independently is halo, OR, NR 2 , NROR, NRNR 2 , SR, SOR, SO 2 R, SO 2
- R 4 is H or optionally substituted member selected from the group consisting of C 1 -C 6 alkyl, C2-C6 heteroalkyl, and C1-C6 acyl; each R is independently H or an optionally substituted member selected from the group consisting of C 1-10 alkyl, C 2-10 alkenyl, C 2-10 heteroalkyl, C 3-8 carbocyclic ring, and C 3-8 heterocyclic ring optionally fused to an additional optionally substituted carbocyclic or heterocyclic; or R 5 is a C 1-10 alkyl, C 2-10 alkenyl, or C 2-10 heteroalkyl substituted with an optionally substituted C 3-8 carbocyclic ring or C 3-8 heterocyclic ring; and in each -NR 4 R 5 , R 4 and R 5 together with N may form an optionally substituted 3-8 membered ring, which may optionally contain an additional heteroatom selected from N, O and S as a ring member; provided that if R 5 in Formula IV is phenyl
- each R 7 is independently H or an optionally substituted member selected from the group consisting of C 1-10 alkyl, C 2-10 alkenyl, C 2-10 heteroalkyl, C 3-8 carbocyclic ring, and C 3-8 heterocyclic ring optionally fused to an additional optionally substituted carbocyclic or heterocyclic ring; or R 7 is a C 1-10 alkyl, C 2-10 alkenyl, or C 2-10 heteroalkyl substituted with an optionally substituted C 3-8 carbocyclic ring or C 3-8 heterocyclic ring.
- R 3P is a polar substituent and each R 3A , R 3B , R 3C and R 3D independently is selected from R 3 substituents.
- the ring containing Z 1 -Z 4 is independently an optionally substituted pyridine, pyrimidine or pyridazine ring.
- B17 The compound of any one of embodiments B1-B16, wherein R 5 is an optionally substituted 3-8 membered ring.
- B 18 The compound of any one of embodiments B1-B 16, wherein R 5 is a C 1-10 alkyl group substituted with an optionally substituted 3-8 membered ring.
- each Z 1 , Z 2 , Z 3 , and Z 4 is N or CR 3 and none, one or two of Z 1 , Z 2 , Z 3 , and Z 4 is N; each R 3 and R 6 is independently H or an optionally substituted C1-C8 alkyl, C2-C8 heteroalkyl, C2-C8 alkenyl, C2-C8 heteroalkenyl, C2-C8 alkynyl, C2-C8 heteroalkynyl, C1-C8 acyl, C2-C8 heteroacyl, C6-C10 aryl, C5-C12 heteroaryl, C7-C12 arylalkyl, or C6-C12 heteroarylalkyl group, or each R 3 and R 6 can be halo, OR, NR 2 , NROR, NRNR 2 , SR, SOR, SO 2 R, SO 2 NR 2 , NRSO 2 R, NR
- R 4 is H or optionally substituted member selected from the group consisting of C 1 -C 6 alkyl, C2-C6 heteroalkyl, and C1-C6 acyl; each R 5 is independently H or an optionally substituted member selected from the group consisting of C 1-10 alkyl, C 2-10 alkenyl, C 2-10 heteroalkyl, C 3-8 carbocyclic ring, and C 3-8 heterocyclic ring optionally fused to an additional optionally substituted carbocyclic or heterocyclic; or R 5 is a C 1-10 alkyl, C 2-10 alkenyl, or C 2-10 heteroalkyl substituted with an optionally substituted C 3-8 carbocyclic ring or C 3-8 heterocyclic ring; and in each -NR 4 R 5 , R 4 and R 5 together with N may form an optionally substituted 3-8 membered ring, which may optionally contain an additional heteroatom selected from N, O and S as a ring member.
- each R 7 is independently H or an optionally substituted member selected from the group consisting of C 1-10 alkyl, C 2-10 alkenyl, C 2-10 heteroalkyl, C 3-8 carbocyclic ring, and C 3-8 heterocyclic ring optionally fused to an additional optionally substituted carbocyclic or heterocyclic ring; or R 7 is a C 1-10 alkyl, C 2-10 alkenyl, or C 2-10 heteroalkyl substituted with an optionally substituted C 3-8 carbocyclic ring or C 3-8 heterocyclic ring.
- R is a polar substituent and each R , R , R and R independently is selected from R 3 substituents.
- the compound of embodiment C14, the ring containing Z 1 -Z 4 is independently an optionally substituted pyridine, pyrimidine or pyridazine ring.
- R 4 and R 5 are not both hydrogen, and R 4 and R 5 independently are H, -Y 0 or - LY 1 , wherein Y 0 is an optionally substituted 5-membered ring or optionally substituted 6- membered ring, Y 1 is an optionally substituted 5-membered aryl ring or optionally substituted 6-membered aryl ring, and L is a C1-C20 alkyl linker or C1-C20 alkylene linker.
- R 5 in Formula IX is phenyl, substituted phenyl, -CH(CH 3 )-(CH 2 ) 3 -NEt 2 , -(CH 2 ) 3 -piperazine-(CH 2 ) 3 -NH 2 , cyclohexane or butyl, then one or more of R present is a non-hydrogen moiety.
- a pharmaceutical composition comprising a compound of embodiment C1 and a pharmaceutically acceptable carrier.
- a method for identifying a candidate molecule that interacts with a PARP protein which comprises contacting a composition containing a PARP protein and a compound having a structure of Formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV or XVI with a candidate molecule under conditions in which the compound and the protein interact, and determining whether the amount of the compound that interacts with the protein is modulated relative to a control interaction between the compound and the protein without the candidate molecule, whereby a candidate molecule that modulates the amount of the compound interacting with the protein relative to the control interaction is identified as a candidate molecule that interacts with the protein.
- the PARP protein comprises the amino acid sequence of SEQ ID NO: 1 or a substantially identical variant thereof.
- a method for modulating the activity of a PARP protein which comprises contacting a system comprising the protein with a compound having a structure of Formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV or XVI in an amount effective for modulating the activity of the protein.
- F3 The method of F1 or F2, wherein the system is a cell.
- a method for inhibiting cell proliferation which comprises contacting cells with a compound having a structure of Formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV or XVI in an amount effective to inhibit proliferation of the cells.
- cancer cell line is a breast cancer, prostate cancer, pancreatic cancer, lung cancer, hemopoietic cancer, colorectal cancer, skin cancer, ovary cancer cell line.
- G7 The method of embodiment G1, wherein the cells are in a subject.
- G8 The method of embodiment G1, wherein the cells are in a tumor.
- a method for treating a condition related to aberrant cell proliferation which comprises administering a compound having a structure of Formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV or XVI to a subject in need thereof in an amount effective to treat the cell proliferative condition.
- a method to treat cancer or an inflammatory disorder in a subject in need of such treatment comprising: administering to the subject a therapeutically effective amount of a therapeutic agent having a structure of Formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV or XVI or a pharmaceutically acceptable salt thereof; and administering to the subject a molecule that inhibits PARP or CK2 in an amount that is effective to enhance a desired effect of the therapeutic agent.
- a pharmaceutical composition comprising a therapeutic agent of any of formulas TA1-1, TA2, TA3-1, TA4-1, TA5-1 or TA6 admixed with a molecule that inhibits PARP or CK2, or a pharmaceutically acceptable salt thereof.
- composition of embodiment 17, wherein the molecule that inhibits PARP or CK2 is a PARP inhibitor and is a known compound shown above, or is GPI 15427, GPI 16539.
- composition of embodiment 17, wherein the molecule that inhibits PARP or CK2 is a compound of Formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV or XVI as described herein, or a pharmaceutically acceptable salt thereof.
- composition of embodiment 19, wherein the therapeutic agent is a compound of formula TA2 or a pharmaceutically acceptable salt thereof.
- a therapeutic composition comprising: a therapeutically effective amount of a therapeutic agent of the formula TA2:
- a PARP inhibitor or a pharmaceutically acceptable salt of a PARP inhibitor admixed with an amount of a PARP inhibitor or a pharmaceutically acceptable salt of a PARP inhibitor, wherein the PARP inhibitor is selected from the group consisting of GPI 15427, GPI 16539, and the known compounds shown above; and wherein the amount of the PARP inhibitor or the pharmaceutically acceptable salt of a PARP inhibitor is an amount that is effective to enhance a desired effect of the therapeutic agent.
- Z 5 is N or CR 6A ; each R 6A , R 6B , R 6C and R 8 independently is H or an optionally substituted C1-C8 alkyl, C2-C8 heteroalkyl, C2-C8 alkenyl, C2-C8 heteroalkenyl, C2-C8 alkynyl, C2-C8 heteroalkynyl, C1-C8 acyl, C2-C8 heteroacyl, C6-C10 aryl, C5-C12 heteroaryl, C7-C12 arylalkyl, or C6-C12 heteroarylalkyl group, or each R 6A , R 6B , R 6C and R 8 independently is halo, CF 3 , CFN, OR, NR 2 , NROR, NRNR 2 , SR, SOR, SO 2 R, SO 2 NR 2 , NRSO 2 R, NRCONR 2 , NRCOOR, NRCOR, CN, COOR, carboxy biois
- R 9 is independently halo, OR, NR 2 , NROR, NRNR 2 , SR, SOR, SO 2 R, SO 2 NR 2 , NRSO 2 R, NRCONR 2 , NRCOOR, NRCOR, CN, COOR, CONR 2 , OOCR, COR, or NO 2 , wherein each R is independently H or C1-C8 alkyl, C2-C8 heteroalkyl, C2-C8 alkenyl, C2-C8 heteroalkenyl, C2-C8 alkynyl, C2-C8 heteroalkynyl, C1-C8 acyl, C2-C8 heteroacyl, C6-C10 aryl, C5-C10 heteroaryl, C7-C12 arylalkyl, or C6-C12 heteroarylalkyl, and wherein two R on the same atom or on adjacent atoms can be linked to form a 3-8 membered ring, optionally containing one or more N, O
- a method for identifying a candidate molecule that interacts with a serine- threonine protein kinase which comprises: contacting a composition containing a serine-threonine protein kinase and a compound having a structure of Formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV or XVI under conditions in which the compound and the protein interact with a candidate molecule, and determining whether the amount of the compound that interacts with the protein is modulated relative to a control interaction between the compound and the protein without the candidate molecule, whereby a candidate molecule that modulates the amount of the compound interacting with the protein relative to the control interaction is identified as a candidate molecule that interacts with the protein.
- N2 The method of embodiment N1, wherein the serine-threonine protein kinase is a human serine-threonine protein kinase.
- N3 The method of embodiment N1, wherein the serine-threonine protein kinase is selected from the group consisting of CK2, CK2 ⁇ 2, Pim-1, CDK1/cyclinB, c-RAF, Mer, MELK, DYRK2, Flt3, Flt3 (D835Y), Flt4, HIPK3, HIPK2, ZIPK and ZIPK.
- a method for modulating a serine-threonine protein kinase activity which comprises contacting a system comprising a serine-threonine protein kinase protein with a compound of Formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV or XVI in an amount effective for modulating the activity of the protein.
- a method for treating pain or inflammation in a subject which comprises administering a compound of Formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV or XVI to a subject in need thereof in an amount effective to treat the pain or the inflammation.
- a method for identifying a compound that reduces inflammation or pain which comprises: contacting a system with a compound of Formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV or XVI; and detecting a pain signal or inflammation signal in the system, whereby a compound that modulates the pain signal or inflammation signal relative to a control molecule is identified as a compound that reduces inflammation of pain.
- a method for inhibiting angiogenesis in a subject which comprises administering a compound of Formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV or XVI to a subject in need thereof in an amount effective to inhibit the angiogenesis.
- a method for identifying a compound that modulates angiogenesis which comprises contacting a system with a compound of Formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV or XVI; and detecting angiogenesis or an angiogenesis signal in the system, whereby a compound that modulates the angiogenesis or angiogenesis signal relative to a control molecule is identified as a compound that modulates angiogenesis.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
Abstract
Description
Claims
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2007289065A AU2007289065B2 (en) | 2006-09-01 | 2007-08-31 | Serine-threonine protein kinase and PARP modulators |
BRPI0719123-5A BRPI0719123A2 (en) | 2006-09-01 | 2007-08-31 | SERINA-TREONINE PROTEIN KINASE AND PARP MODULATORS |
JP2009526946A JP5399905B2 (en) | 2006-09-01 | 2007-08-31 | Serine-threonine protein kinase and PARP regulator |
ES07841767.2T ES2528316T3 (en) | 2006-09-01 | 2007-08-31 | Serine-threonine protein kinase and PARP modulators |
CA2661842A CA2661842C (en) | 2006-09-01 | 2007-08-31 | Tricyclic heteroaryl compounds and their use as serine-threonine protein kinases and parp modulators |
DK07841767.2T DK2061765T3 (en) | 2006-09-01 | 2007-08-31 | Serine-threonine protein kinase AND PARP-MODULATOR |
CN200780037330.6A CN101528704B (en) | 2006-09-01 | 2007-08-31 | Serine-threonine protein kinase and PARP modulators |
EP07841767.2A EP2061765B1 (en) | 2006-09-01 | 2007-08-31 | Serine-threonine protein kinase and PARP modulators |
MX2009002298A MX2009002298A (en) | 2006-09-01 | 2007-08-31 | Serine-threonine protein kinase and parp modulators. |
PL07841767T PL2061765T3 (en) | 2006-09-01 | 2007-08-31 | Serine-threonine protein kinase and PARP modulators |
IL197088A IL197088A0 (en) | 2006-09-01 | 2009-02-17 | Serine-threonine protein kinase and parp modulators |
NO20090854A NO20090854L (en) | 2006-09-01 | 2009-02-25 | Serine-threonine protein kinase and PARP modulators |
HK10102364.2A HK1137448A1 (en) | 2006-09-01 | 2010-03-05 | Serine-threonine protein kinase and parp modulators - parp |
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US84206106P | 2006-09-01 | 2006-09-01 | |
US60/842,061 | 2006-09-01 | ||
US84454206P | 2006-09-13 | 2006-09-13 | |
US60/844,542 | 2006-09-13 | ||
US84668306P | 2006-09-22 | 2006-09-22 | |
US60/846,683 | 2006-09-22 | ||
US87393606P | 2006-12-07 | 2006-12-07 | |
US60/873,936 | 2006-12-07 | ||
US89571607P | 2007-03-19 | 2007-03-19 | |
US60/895,716 | 2007-03-19 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008028168A2 true WO2008028168A2 (en) | 2008-03-06 |
WO2008028168A3 WO2008028168A3 (en) | 2008-11-13 |
Family
ID=39136972
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/077464 WO2008028168A2 (en) | 2006-09-01 | 2007-08-31 | Serine-threonine protein kinase and parp modulators |
Country Status (17)
Country | Link |
---|---|
US (2) | US7956064B2 (en) |
EP (1) | EP2061765B1 (en) |
JP (1) | JP5399905B2 (en) |
KR (1) | KR20090050094A (en) |
AU (1) | AU2007289065B2 (en) |
BR (1) | BRPI0719123A2 (en) |
CA (2) | CA2661842C (en) |
DK (1) | DK2061765T3 (en) |
ES (1) | ES2528316T3 (en) |
HK (1) | HK1137448A1 (en) |
IL (1) | IL197088A0 (en) |
MX (1) | MX2009002298A (en) |
NO (1) | NO20090854L (en) |
PL (1) | PL2061765T3 (en) |
PT (1) | PT2061765E (en) |
RU (1) | RU2681209C2 (en) |
WO (1) | WO2008028168A2 (en) |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010026122A1 (en) | 2008-09-02 | 2010-03-11 | Novartis Ag | Heterocyclic pim-kinase inhibitors |
WO2009155527A3 (en) * | 2008-06-19 | 2010-06-24 | Progenics Pharmaceuticals, Inc. | Phosphatidylinositol 3 kinase inhibitors |
WO2010080170A1 (en) * | 2009-01-08 | 2010-07-15 | Cylene Pharmaceuticals, Inc. | Combination therapies for neoplastic disorders |
WO2010121225A2 (en) * | 2009-04-17 | 2010-10-21 | Cylene Pharmaceuticals, Inc. | Method of treating disorders associated with protein kinase ck2 activity |
WO2011011199A1 (en) * | 2009-07-23 | 2011-01-27 | Cylene Pharmaceuticals, Inc. | Combination therapies with ck2 modulators |
WO2011025859A1 (en) * | 2009-08-26 | 2011-03-03 | Cylene Pharmaceuticals, Inc. | Condensed quinolines as protein kinase modulators |
US20110160240A1 (en) * | 2009-11-23 | 2011-06-30 | Cylene Pharmaceuticals, Inc. | Polymorphs and salts of a kinase inhibitor |
EP2364983A2 (en) * | 2008-11-11 | 2011-09-14 | Jeil Pharmaceutical Co., Ltd. | Novel tricyclic derivative or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition containing the same |
DE102010025173A1 (en) | 2010-06-25 | 2011-12-29 | Claudia Götz | Use of dibenzofuranone derivatives for inhibiting kinases |
JP2012512246A (en) * | 2008-12-17 | 2012-05-31 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | C-ring modified tricyclic benzonaphthyridinone protein kinase inhibitors and uses thereof |
JP2013500989A (en) * | 2009-07-30 | 2013-01-10 | 武田薬品工業株式会社 | Poly (ADP-ribose) polymerase (PARP) inhibitor |
EP2552206A1 (en) * | 2010-03-29 | 2013-02-06 | OncoTherapy Science, Inc. | Trycyclic compounds and pbk inhibitors containing the same |
JP2013509431A (en) * | 2009-10-29 | 2013-03-14 | ブリストル−マイヤーズ スクイブ カンパニー | Tricyclic heterocyclic compounds |
US9062043B2 (en) | 2006-09-01 | 2015-06-23 | Senhwa Biosciences, Inc. | Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators |
US10040804B2 (en) | 2016-12-21 | 2018-08-07 | Biotheryx, Inc. | Compounds targeting proteins, compositions, methods, and uses thereof |
US10633354B2 (en) | 2016-09-02 | 2020-04-28 | Bristol-Myers Squibb Company | Substituted tricyclic heterocyclic compounds |
US11046646B2 (en) | 2017-08-09 | 2021-06-29 | Bristol-Myers Squibb Company | Alkylphenyl compounds |
US11059784B2 (en) | 2017-08-09 | 2021-07-13 | Bristol-Myers Squibb Company | Oxime ether compounds |
EP3866804A4 (en) * | 2018-10-19 | 2022-08-03 | Senhwa Biosciences, Inc. | Combinations for immune-modulation in cancer treatment |
US11498929B2 (en) | 2019-06-17 | 2022-11-15 | Hibercell, Inc. | Chromenopyrimidine derivatives as phosphatidylinsitol phosphate kinase inhibitors |
US11584763B2 (en) | 2017-12-22 | 2023-02-21 | Hibercell, Inc. | Chromenopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors |
WO2023126951A1 (en) * | 2022-01-03 | 2023-07-06 | Yeda Research And Development Co. Ltd. | Inhibitors of autophagy-related protein-protein interactions |
US11713299B2 (en) | 2016-12-22 | 2023-08-01 | Global Blood Therapeutics, Inc. | Histone methyltransferase inhibitors |
US11866436B2 (en) * | 2021-03-01 | 2024-01-09 | Cambridge Enterprise Limited | Benzo[c][2,6]naphthyridine derivatives, compositions and therapeutic uses thereof |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006068760A2 (en) | 2004-11-19 | 2006-06-29 | The Regents Of The University Of California | Anti-inflammatory pyrazolopyrimidines |
MX2008012928A (en) | 2006-04-04 | 2009-03-06 | Univ California | P13 kinase antagonists. |
WO2009046448A1 (en) | 2007-10-04 | 2009-04-09 | Intellikine, Inc. | Chemical entities and therapeutic uses thereof |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
CN104926815B (en) | 2008-01-04 | 2017-11-03 | 英特利凯恩有限责任公司 | Some chemical entities, composition and method |
WO2009108912A1 (en) * | 2008-02-29 | 2009-09-03 | Cylene Pharmaceuticals, Inc. | Protein kinase modulators |
JP5547099B2 (en) | 2008-03-14 | 2014-07-09 | インテリカイン, エルエルシー | Kinase inhibitors and methods of use |
US8993580B2 (en) | 2008-03-14 | 2015-03-31 | Intellikine Llc | Benzothiazole kinase inhibitors and methods of use |
US20110224223A1 (en) * | 2008-07-08 | 2011-09-15 | The Regents Of The University Of California, A California Corporation | MTOR Modulators and Uses Thereof |
BRPI0915231A2 (en) | 2008-07-08 | 2018-06-12 | Intellikine Inc | kinase inhibitor compounds and methods of use |
WO2010036380A1 (en) | 2008-09-26 | 2010-04-01 | Intellikine, Inc. | Heterocyclic kinase inhibitors |
US8697709B2 (en) | 2008-10-16 | 2014-04-15 | The Regents Of The University Of California | Fused ring heteroaryl kinase inhibitors |
US8476282B2 (en) | 2008-11-03 | 2013-07-02 | Intellikine Llc | Benzoxazole kinase inhibitors and methods of use |
EP2427195B1 (en) | 2009-05-07 | 2019-05-01 | Intellikine, LLC | Heterocyclic compounds and uses thereof |
AU2010295619A1 (en) * | 2009-09-16 | 2012-05-10 | Cylene Pharmaceuticals, Inc. | Novel tricyclic protein kinase modulators |
BR112012007555B1 (en) | 2009-10-02 | 2020-09-29 | Cylene Pharmaceuticals, Inc | IN VITRO METHODS FOR PREVENTING THE SENSITIVITY AND RESPONSE OF DISEASES MEDIATED BY PROTEIN KINASE CK2 TO CK2 INHIBITORS |
US8980899B2 (en) | 2009-10-16 | 2015-03-17 | The Regents Of The University Of California | Methods of inhibiting Ire1 |
AT509045B1 (en) * | 2010-01-29 | 2011-06-15 | Planta Naturstoffe Vertriebsges M B H | COMPOUNDS FOR THE TREATMENT OF ASTHMA BRONCHIALE |
CN103002738A (en) | 2010-05-21 | 2013-03-27 | 英特利凯恩有限责任公司 | Chemical compounds, compositions and methods for kinase modulation |
US20120129849A1 (en) * | 2010-10-22 | 2012-05-24 | Cylene Pharmaceuticals, Inc. | Deuterated serine-threonine protein kinase modulators |
AU2011326427B2 (en) | 2010-11-10 | 2016-01-07 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
BR112013017670B1 (en) | 2011-01-10 | 2022-07-19 | Infinity Pharmaceuticals, Inc | PROCESSES FOR PREPARING ISOQUINOLINONES AND SOLID FORMS OF ISOQUINOLINONES |
WO2012148540A1 (en) | 2011-02-23 | 2012-11-01 | Intellikine, Llc | Combination of kanase inhibitors and uses threof |
AR088218A1 (en) | 2011-07-19 | 2014-05-21 | Infinity Pharmaceuticals Inc | USEFUL HETEROCICLICAL COMPOUNDS AS PI3K INHIBITORS |
WO2013012915A1 (en) | 2011-07-19 | 2013-01-24 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
CA2846431A1 (en) | 2011-08-29 | 2013-03-07 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
WO2013077921A2 (en) | 2011-09-02 | 2013-05-30 | The Regents Of The University Of California | Substituted pyrazolo[3,4-d]pyrimidines and uses thereof |
BR112014017833A2 (en) | 2012-01-20 | 2021-03-23 | Dennis Brown | USE OF REPLACED HEXITOLS INCLUDING DIANIDROGALACTITOL AND ANALOGS TO TREAT NEOPLASTIC DISEASE AND CANCER STEM CELLS INCLUDING MULTIFORM GLIOBLASTOMA AND MEDULOBLASTOMA |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
ME02651B (en) | 2012-06-13 | 2017-06-20 | Incyte Holdings Corp | Substituted tricyclic compounds as fgfr inhibitors |
US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
EP2872161B1 (en) | 2012-06-26 | 2020-12-16 | Del Mar Pharmaceuticals | Dianhydrogalactitol for use in treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations |
US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
RU2015115631A (en) | 2012-09-26 | 2016-11-20 | Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния | MODULATION IRE1 |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
US11491154B2 (en) | 2013-04-08 | 2022-11-08 | Dennis M. Brown | Therapeutic benefit of suboptimally administered chemical compounds |
CA2909207C (en) | 2013-04-19 | 2021-11-02 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
KR20160099081A (en) | 2013-07-26 | 2016-08-19 | 업데이트 파마 인코포레이트 | Combinatorial methods to improve the therapeutic benefit of bisantrene |
MY175778A (en) | 2013-10-04 | 2020-07-08 | Infinity Pharmaceuticals Inc | Heterocyclic compounds and uses thereof |
US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
EP3089965B1 (en) | 2014-01-05 | 2018-08-29 | Washington University | Radiolabeled tracers for poly (adp-ribose) polymerase-1 (parp-1), methods and uses therefor |
CN106456628A (en) | 2014-03-19 | 2017-02-22 | 无限药品股份有限公司 | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
CN106659765B (en) | 2014-04-04 | 2021-08-13 | 德玛医药 | Use of dianhydrogalactitol and analogs or derivatives thereof for treating non-small cell lung cancer and ovarian cancer |
WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
CR20170390A (en) | 2015-02-20 | 2017-10-23 | Incyte Holdings Corp | BICYCLE HETEROCICLES AS FGFR INHIBITORS |
MA41551A (en) | 2015-02-20 | 2017-12-26 | Incyte Corp | BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS |
EP3265560B1 (en) | 2015-03-02 | 2021-12-08 | Sinai Health System | Homologous recombination factors |
WO2016200101A2 (en) * | 2015-06-09 | 2016-12-15 | 제일약품주식회사 | Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same |
WO2017048702A1 (en) | 2015-09-14 | 2017-03-23 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same |
US10759806B2 (en) | 2016-03-17 | 2020-09-01 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors |
US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US10213449B2 (en) | 2016-06-16 | 2019-02-26 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for treating medulloblastoma |
MX2018016227A (en) | 2016-06-24 | 2019-07-08 | Infinity Pharmaceuticals Inc | Combination therapies. |
KR20180062804A (en) * | 2016-12-01 | 2018-06-11 | 사회복지법인 삼성생명공익재단 | Pharmaceutical composition for preventing or treating ischemic acute kidney injury comprising tricyclic derivatives or pharmaceutically acceptable salts thereof |
AR111960A1 (en) | 2017-05-26 | 2019-09-04 | Incyte Corp | CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION |
US11932606B2 (en) * | 2017-07-31 | 2024-03-19 | The Regents Of The University Of California | Anti-cancer/anti-fibrosis compounds |
US11071727B2 (en) | 2018-01-26 | 2021-07-27 | Northwestern University | Therapeutic targeting of proteolytic cleavage of the mixed lineage leukemia gene product (MLL1) by taspase1 using kinase inhibitors |
WO2019213544A2 (en) | 2018-05-04 | 2019-11-07 | Incyte Corporation | Solid forms of an fgfr inhibitor and processes for preparing the same |
BR112020022373A2 (en) | 2018-05-04 | 2021-02-02 | Incyte Corporation | salts of a fgfr inhibitor |
GB201902759D0 (en) | 2019-02-28 | 2019-04-17 | Benevolentai Bio Ltd | Compositions and uses thereof |
WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
JOP20220083A1 (en) | 2019-10-14 | 2023-01-30 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
JP2023505258A (en) | 2019-12-04 | 2023-02-08 | インサイト・コーポレイション | Tricyclic heterocycles as FGFR inhibitors |
BR112022010664A2 (en) | 2019-12-04 | 2022-08-16 | Incyte Corp | DERIVATIVES OF A FGFR INHIBITOR |
WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
AU2021249224A1 (en) | 2020-03-30 | 2022-12-01 | Senhwa Biosciences, Inc. | Antiviral compounds and method for treating hepatotropic viral infection, particularly hepatitis B and hepatitis D |
TW202313611A (en) | 2021-06-09 | 2023-04-01 | 美商英塞特公司 | Tricyclic heterocycles as fgfr inhibitors |
US11891395B1 (en) * | 2023-08-25 | 2024-02-06 | King Faisal University | 5-substituted aminopyrazino[2′,1′:2,3]imidazo[4,5-C][2,7]naphthyridine compounds as CK2 inhibitors |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2355084A1 (en) * | 1972-11-06 | 1974-05-16 | Guidotti & C Spa Labor | COMPOUNDS HAVING A GASTIC ACID SECRETION-INHIBITING EFFECT AND PROCESS FOR THEIR PRODUCTION |
US3859312A (en) * | 1972-12-21 | 1975-01-07 | Richardson Merrell Inc | 6h-dibenzo(b,d)pyran-6-ones |
JPS5111797A (en) * | 1974-07-18 | 1976-01-30 | Kojin Kk | Shinkina 44 chikanamino 2*66 jiokisoopirido * 3*22c * isokinorinjudotaino seizohoho |
JPS5377067A (en) * | 1976-12-20 | 1978-07-08 | Teijin Ltd | Preparation of phenanthridone-carboxylic acids |
JPS53103476A (en) * | 1977-02-18 | 1978-09-08 | Ube Ind Ltd | 6(5h)-phenanthridinone-3,8-dicarboxylic acid and process its preparation |
US4959361A (en) * | 1987-12-18 | 1990-09-25 | Hoffmann-La Roche Inc. | Triazolo(4,3-A)(1,4)benzodiazepines and thieno (3,2-F)(1,2,4)triazolo(4,3-A)(1,4)diazepine compounds which have useful activity as platelet activating factor (PAF) antagonists |
JPH05197241A (en) | 1992-01-21 | 1993-08-06 | Sharp Corp | Electrophotographic device |
US5328904A (en) * | 1993-01-27 | 1994-07-12 | Merck & Co., Inc. | 2-phenanthridinyl carbapenem antibacterial agents |
JP3690825B2 (en) * | 1993-07-26 | 2005-08-31 | エーザイ株式会社 | Tricyclic heterocycle-containing sulfonamides and sulfonic acid ester derivatives |
EP0716661B1 (en) * | 1993-09-09 | 2000-04-05 | Scios Inc. | Pseudo- and non-peptide bradykinin receptor antagonists |
US5624677A (en) * | 1995-06-13 | 1997-04-29 | Pentech Pharmaceuticals, Inc. | Controlled release of drugs delivered by sublingual or buccal administration |
DK0937074T3 (en) * | 1996-11-11 | 2003-06-23 | Altana Pharma Ag | Benzonaphthyridines as bronchial therapeutics |
JPH10282804A (en) | 1997-04-07 | 1998-10-23 | Ricoh Co Ltd | Image forming device |
US20020022636A1 (en) * | 1997-09-03 | 2002-02-21 | Jia-He Li | Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity |
US6110929A (en) | 1998-07-28 | 2000-08-29 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
US6531464B1 (en) * | 1999-12-07 | 2003-03-11 | Inotek Pharmaceutical Corporation | Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives |
JP2001315103A (en) * | 2000-05-01 | 2001-11-13 | Harima Chem Inc | Method for manufacturing sliced veneer decorative plywood |
AU2001264595A1 (en) * | 2000-05-19 | 2001-12-03 | Guilford Pharmaceuticals Inc. | Sulfonamide and carbamide derivatives of 6(5h)phenanthridinones and their uses |
JP2002014550A (en) | 2000-06-30 | 2002-01-18 | Ricoh Co Ltd | Device and method for transfer, and device and method for image forming |
HUP0302167A3 (en) * | 2000-10-02 | 2010-03-29 | Janssen Pharmaceutica Nv | Quinoline derivatives as metabotropic glutamate receptor antagonists, pharmaceutical compositions containing them and process for producing them |
JP2002132065A (en) | 2000-10-23 | 2002-05-09 | Ricoh Co Ltd | Image forming device |
JP2002156808A (en) | 2000-11-20 | 2002-05-31 | Ricoh Co Ltd | Color image forming device |
ATE478664T1 (en) * | 2000-12-01 | 2010-09-15 | Eisai Inc | AZAPHENANTHRIDONE DERIVATIVES AND THEIR USE AS PARP INHIBITORS |
US20030069295A1 (en) | 2001-08-15 | 2003-04-10 | Gliatech, Inc. | Use of histamine H3 receptor inverse agonists for the control of appetite and treatment of obesity |
AUPS137402A0 (en) * | 2002-03-26 | 2002-05-09 | Fujisawa Pharmaceutical Co., Ltd. | Novel tricyclic compounds |
US7507727B2 (en) * | 2003-04-07 | 2009-03-24 | Cylene Pharmaceuticals, Inc. | Substituted quinobenzoxazine analogs and methods of using thereof |
SG150533A1 (en) * | 2003-11-20 | 2009-03-30 | Janssen Pharmaceutica Nv | 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2- quinoxalinones as poly(adp-ribose) polymerase inhibitors |
CN1922171B (en) * | 2004-02-26 | 2012-10-17 | Aska制药株式会社 | Pyrimidine derivative |
EP1652841A1 (en) | 2004-04-30 | 2006-05-03 | Switch Biotech Aktiengesellschaft | Novel phenantridine analogues and their use as inhibitors of hyperproliferation of T cells and/or keratinocytes |
US7816406B2 (en) | 2004-09-17 | 2010-10-19 | Cylene Pharmaceuticals, Inc. | Quinolone analogs |
CA2604787A1 (en) * | 2005-04-15 | 2006-10-26 | Cylene Pharmaceuticals, Inc. | Quinobenzoxazine analogs and methods of using thereof |
WO2007051119A1 (en) * | 2005-10-26 | 2007-05-03 | Mgi Gp, Inc. | Methods and compositions of parp inhibitors as potentiators in cancer therapy |
WO2008016707A2 (en) * | 2006-08-02 | 2008-02-07 | The Johns Hopkins University | Use of il-6 in the diagnosis and treatment of neuroinflammatory conditions |
PL2061765T3 (en) | 2006-09-01 | 2015-04-30 | Senhwa Biosciences Inc | Serine-threonine protein kinase and PARP modulators |
WO2009108912A1 (en) * | 2008-02-29 | 2009-09-03 | Cylene Pharmaceuticals, Inc. | Protein kinase modulators |
-
2007
- 2007-08-31 PL PL07841767T patent/PL2061765T3/en unknown
- 2007-08-31 US US11/849,230 patent/US7956064B2/en active Active
- 2007-08-31 WO PCT/US2007/077464 patent/WO2008028168A2/en active Application Filing
- 2007-08-31 CA CA2661842A patent/CA2661842C/en active Active
- 2007-08-31 BR BRPI0719123-5A patent/BRPI0719123A2/en not_active IP Right Cessation
- 2007-08-31 JP JP2009526946A patent/JP5399905B2/en active Active
- 2007-08-31 ES ES07841767.2T patent/ES2528316T3/en active Active
- 2007-08-31 CA CA2974246A patent/CA2974246C/en active Active
- 2007-08-31 AU AU2007289065A patent/AU2007289065B2/en active Active
- 2007-08-31 PT PT78417672T patent/PT2061765E/en unknown
- 2007-08-31 KR KR1020097006608A patent/KR20090050094A/en not_active Application Discontinuation
- 2007-08-31 DK DK07841767.2T patent/DK2061765T3/en active
- 2007-08-31 EP EP07841767.2A patent/EP2061765B1/en active Active
- 2007-08-31 MX MX2009002298A patent/MX2009002298A/en active IP Right Grant
-
2009
- 2009-02-17 IL IL197088A patent/IL197088A0/en unknown
- 2009-02-25 NO NO20090854A patent/NO20090854L/en not_active Application Discontinuation
-
2010
- 2010-03-05 HK HK10102364.2A patent/HK1137448A1/en unknown
-
2011
- 2011-02-25 US US13/035,640 patent/US9062043B2/en active Active
-
2013
- 2013-07-04 RU RU2013130739A patent/RU2681209C2/en active
Non-Patent Citations (2)
Title |
---|
None |
See also references of EP2061765A4 |
Cited By (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9062043B2 (en) | 2006-09-01 | 2015-06-23 | Senhwa Biosciences, Inc. | Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators |
WO2009155527A3 (en) * | 2008-06-19 | 2010-06-24 | Progenics Pharmaceuticals, Inc. | Phosphatidylinositol 3 kinase inhibitors |
CN102197032A (en) * | 2008-09-02 | 2011-09-21 | 诺瓦提斯公司 | Heterocyclic PIM-kinase inhibitors |
US8759338B2 (en) | 2008-09-02 | 2014-06-24 | Novartis Ag | Heterocyclic kinase inhibitors |
WO2010026122A1 (en) | 2008-09-02 | 2010-03-11 | Novartis Ag | Heterocyclic pim-kinase inhibitors |
US8815891B2 (en) | 2008-11-11 | 2014-08-26 | Je Il Pharmaceutical Co., Ltd. | Tricyclic derivative or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition containing the same |
EP2364983A4 (en) * | 2008-11-11 | 2012-05-09 | Jeil Pharmaceutical Co Ltd | Novel tricyclic derivative or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition containing the same |
EP2364983A2 (en) * | 2008-11-11 | 2011-09-14 | Jeil Pharmaceutical Co., Ltd. | Novel tricyclic derivative or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition containing the same |
CN102245612B (en) * | 2008-11-11 | 2014-11-05 | 第一药品株式会社 | Novel tricyclic derivative or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition containing the same |
CN102245612A (en) * | 2008-11-11 | 2011-11-16 | 第一药品株式会社 | Novel tricyclic derivative or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition containing the same |
JP2012508273A (en) * | 2008-11-11 | 2012-04-05 | ジェ イル ファーマシューティカル カンパニー リミテッド | Novel tricyclic derivatives or pharmaceutically acceptable salts thereof, processes for their preparation and pharmaceutical compositions containing them |
US9938268B2 (en) | 2008-12-17 | 2018-04-10 | Merck Patent Gmbh | C-ring modified tricyclic benzonaphthiridinone protein kinase inhibitors and use thereof |
JP2012512246A (en) * | 2008-12-17 | 2012-05-31 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | C-ring modified tricyclic benzonaphthyridinone protein kinase inhibitors and uses thereof |
WO2010080170A1 (en) * | 2009-01-08 | 2010-07-15 | Cylene Pharmaceuticals, Inc. | Combination therapies for neoplastic disorders |
CN102341107A (en) * | 2009-01-08 | 2012-02-01 | 赛林药物股份有限公司 | Combination therapies for neoplastic disorders |
WO2010121225A3 (en) * | 2009-04-17 | 2011-01-06 | Cylene Pharmaceuticals, Inc. | Method of treating disorders associated with protein kinase ck2 activity |
WO2010121225A2 (en) * | 2009-04-17 | 2010-10-21 | Cylene Pharmaceuticals, Inc. | Method of treating disorders associated with protein kinase ck2 activity |
CN102497862A (en) * | 2009-07-23 | 2012-06-13 | 赛林药物股份有限公司 | Combination therapies with ck2 modulators |
CN102497862B (en) * | 2009-07-23 | 2015-03-25 | 生华生物科技股份有限公司 | Combination therapies with ck2 modulators |
WO2011011199A1 (en) * | 2009-07-23 | 2011-01-27 | Cylene Pharmaceuticals, Inc. | Combination therapies with ck2 modulators |
JP2013500989A (en) * | 2009-07-30 | 2013-01-10 | 武田薬品工業株式会社 | Poly (ADP-ribose) polymerase (PARP) inhibitor |
CN102596969A (en) * | 2009-08-26 | 2012-07-18 | 赛林药物股份有限公司 | Condensed quinolines as protein kinase modulators |
WO2011025859A1 (en) * | 2009-08-26 | 2011-03-03 | Cylene Pharmaceuticals, Inc. | Condensed quinolines as protein kinase modulators |
JP2013509431A (en) * | 2009-10-29 | 2013-03-14 | ブリストル−マイヤーズ スクイブ カンパニー | Tricyclic heterocyclic compounds |
US9216972B2 (en) | 2009-10-29 | 2015-12-22 | Bristol-Myers Squibb Company | Tricyclic heterocyclic compounds |
US8853235B2 (en) * | 2009-11-23 | 2014-10-07 | Senhwa Biosciences, Inc. | Polymorphs and salts of a kinase inhibitor |
US20110160240A1 (en) * | 2009-11-23 | 2011-06-30 | Cylene Pharmaceuticals, Inc. | Polymorphs and salts of a kinase inhibitor |
EP2552206A4 (en) * | 2010-03-29 | 2013-08-14 | Oncotherapy Science Inc | Trycyclic compounds and pbk inhibitors containing the same |
US9453025B2 (en) | 2010-03-29 | 2016-09-27 | Oncotherapy Science, Inc. | Tricyclic compounds and PBK inhibitors containing the same |
EP2552206A1 (en) * | 2010-03-29 | 2013-02-06 | OncoTherapy Science, Inc. | Trycyclic compounds and pbk inhibitors containing the same |
US8962648B2 (en) | 2010-03-29 | 2015-02-24 | Oncotherapy Science, Inc. | Tricyclic compounds and PBK inhibitors containing the same |
TWI503323B (en) * | 2010-03-29 | 2015-10-11 | Oncotherapy Science Inc | Tricyclic compounds and pbk inhibitors containing the same |
KR101757502B1 (en) | 2010-03-29 | 2017-07-12 | 온코세라피 사이언스 가부시키가이샤 | Trycyclic compounds and pbk inhibitors containing the same |
WO2011161151A1 (en) | 2010-06-25 | 2011-12-29 | Joachim Jose | Use of dibenzofuranone derivatives to inhibit kinases |
DE102010025173A1 (en) | 2010-06-25 | 2011-12-29 | Claudia Götz | Use of dibenzofuranone derivatives for inhibiting kinases |
US9303005B2 (en) | 2010-06-25 | 2016-04-05 | Joachim Jose | Use of dibenzofuranone derivatives to inhibit kinases |
US10633354B2 (en) | 2016-09-02 | 2020-04-28 | Bristol-Myers Squibb Company | Substituted tricyclic heterocyclic compounds |
US11345714B2 (en) | 2016-12-21 | 2022-05-31 | Biotheryx, Inc. | Compounds targeting proteins, compositions, methods, and uses thereof |
US10040804B2 (en) | 2016-12-21 | 2018-08-07 | Biotheryx, Inc. | Compounds targeting proteins, compositions, methods, and uses thereof |
US10336771B2 (en) | 2016-12-21 | 2019-07-02 | Biotheryx, Inc. | Compounds targeting proteins, compositions, methods, and uses thereof |
US10889593B2 (en) | 2016-12-21 | 2021-01-12 | Biotheryx, Inc. | Compounds targeting proteins, compositions, methods, and uses thereof |
US11713299B2 (en) | 2016-12-22 | 2023-08-01 | Global Blood Therapeutics, Inc. | Histone methyltransferase inhibitors |
US11046646B2 (en) | 2017-08-09 | 2021-06-29 | Bristol-Myers Squibb Company | Alkylphenyl compounds |
US11059784B2 (en) | 2017-08-09 | 2021-07-13 | Bristol-Myers Squibb Company | Oxime ether compounds |
US11584763B2 (en) | 2017-12-22 | 2023-02-21 | Hibercell, Inc. | Chromenopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors |
EP3866804A4 (en) * | 2018-10-19 | 2022-08-03 | Senhwa Biosciences, Inc. | Combinations for immune-modulation in cancer treatment |
US11498929B2 (en) | 2019-06-17 | 2022-11-15 | Hibercell, Inc. | Chromenopyrimidine derivatives as phosphatidylinsitol phosphate kinase inhibitors |
US11866436B2 (en) * | 2021-03-01 | 2024-01-09 | Cambridge Enterprise Limited | Benzo[c][2,6]naphthyridine derivatives, compositions and therapeutic uses thereof |
WO2023126951A1 (en) * | 2022-01-03 | 2023-07-06 | Yeda Research And Development Co. Ltd. | Inhibitors of autophagy-related protein-protein interactions |
Also Published As
Publication number | Publication date |
---|---|
PT2061765E (en) | 2015-02-06 |
US20110263581A1 (en) | 2011-10-27 |
AU2007289065B2 (en) | 2013-03-14 |
JP5399905B2 (en) | 2014-01-29 |
DK2061765T3 (en) | 2015-01-26 |
AU2007289065A2 (en) | 2009-06-25 |
EP2061765B1 (en) | 2014-10-22 |
IL197088A0 (en) | 2009-11-18 |
HK1137448A1 (en) | 2010-07-30 |
JP2010502651A (en) | 2010-01-28 |
CA2661842A1 (en) | 2008-03-06 |
US20090264423A2 (en) | 2009-10-22 |
CA2974246C (en) | 2020-02-25 |
BRPI0719123A2 (en) | 2013-12-17 |
WO2008028168A3 (en) | 2008-11-13 |
CA2661842C (en) | 2017-08-22 |
RU2013130739A (en) | 2015-01-10 |
ES2528316T3 (en) | 2015-02-06 |
PL2061765T3 (en) | 2015-04-30 |
EP2061765A4 (en) | 2012-03-21 |
AU2007289065A1 (en) | 2008-03-06 |
MX2009002298A (en) | 2009-06-04 |
NO20090854L (en) | 2009-04-29 |
KR20090050094A (en) | 2009-05-19 |
US7956064B2 (en) | 2011-06-07 |
CA2974246A1 (en) | 2008-03-06 |
US20090105233A1 (en) | 2009-04-23 |
RU2681209C2 (en) | 2019-03-05 |
EP2061765A2 (en) | 2009-05-27 |
US9062043B2 (en) | 2015-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2061765B1 (en) | Serine-threonine protein kinase and PARP modulators | |
JP4964874B2 (en) | Fluorene derivatives, compositions containing the derivatives and uses thereof | |
AU2011288876B2 (en) | Phthalazinone ketone derivative, preparation method thereof, and pharmaceutical use thereof | |
ES2727977T3 (en) | Imidazo [4,5-c] pyridine and pyrrolo [2,3-c] pyridine derivatives as SSAO inhibitors | |
TW202233183A (en) | Novel prmt5 inhibitors | |
US20030158195A1 (en) | 1,6 naphthyridines useful as inhibitors of SYK kinase | |
CN107428731A (en) | 2 substituted hydrogen pyrazole derivatives as cancer therapy drug | |
US7910600B2 (en) | Therapeutic kinase modulators | |
JP2011515337A (en) | Protein kinase modulator | |
JP2018504430A (en) | Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors | |
BRPI0616701A2 (en) | 2-amino-7,8-dihydro-6h-pyrido [4,3-d] pyrimidin-5-ones | |
CN107021963A (en) | Pyrazole fused ring analog derivative, its preparation method and its application in treating cancer, inflammation and immunity disease | |
ES2308260T3 (en) | DERIVATIVES OF IMIDAZOPIRIDINS AS INHIBITORS OF INDUCIBLE NON-SYNTHEASE. | |
CN101528704B (en) | Serine-threonine protein kinase and PARP modulators | |
KR20090080948A (en) | New fluorene derivatives, compositions containing the same and use thereof as inhibitors of the protein chaperone hsp90 | |
WO2003103666A2 (en) | Novel 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones | |
CA2623534A1 (en) | Inhibitors of the hiv integrase enzyme | |
CN118307518A (en) | Polycyclic PARP selective inhibitors | |
Ohashi | Discovery of Novel Hedgehog Signaling Inhibitor | |
CN117886821A (en) | Nitrogen-containing condensed ring derivative inhibitor, preparation method and application thereof | |
大橋知洋 | Discovery of Novel Hedgehog Signaling Inhibitor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780037330.6 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07841767 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 197088 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007289065 Country of ref document: AU Ref document number: 2661842 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009526946 Country of ref document: JP Ref document number: MX/A/2009/002298 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 859/KOLNP/2009 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 575546 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007841767 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020097006608 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2009111854 Country of ref document: RU Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: PI0719123 Country of ref document: BR Kind code of ref document: A2 Effective date: 20090302 |